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Abstract 
In this study, cisplatin-resistant adenocarcinoma breast cancer cell lines, labeled 
MCF-7/R6 and MDA-MB-231/R2 were established by 6 replicative sequential 
treatment of low doses (1 micromolar) over high doses (30 micromolar) of cisplatin and 
chemoresistance was evaluated as apoptotic response to 30 micromolar cisplatin for 48 
hours. Throughout the study parental cells were used as control. 
RNA was isolated to conduct microarray study to analyze 48000 gene probes 
(Illumina Human WG-6 BeadChip).  Gene expression data was analyzed by MATLAB 
2009 and identification of differentially expressed genes were further studied by 
proteomic analysis to understand the drug resistance mechanisms.  
Our data indicated that transcription of drug resistant marker genes, such as 
GSTP1 and ABCB6 were upregulated in MCF-7/R6 cell line. Both intrinsically 
resistant cell line: MDA-MB-231 and acquired resistant cell line: MCF-7/R6 were 
similar in activating NF- kappa-B pathway but not MAP kinase pathway. In MCF-7/R6 
cell line NF-kappa-B pathway was transactivated through p50 subunit, as well as 
translocation of Foxo3a transcription factor into the nucleus.  
Genes responsible for cell death, Foxo family and MAPK levels were found to 
change significantly at protein and genetic level in MCF-7/R6 and MDA-MB-231/R2 
cells.  Phosphorylation levels in transcription factor Foxo1 and Foxo3a were found to 
change MCF-7/R6 cells, indicating resistance to apoptosis. Moreover, cell cycle, tumor 
suppressor and estrogen receptor levels were found to be altered in MCF-7/R6 cell line.  
Our data clearly identify several proteins and pathways which have distinct roles 
in chemoresistance mechanism. This knowledge can be further validated in a clinical 
setting. 
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Özet 
Bu çalışmada, 6 tekrarlı ardışık düşük doz (1 mikromolar) ilaç muamelesini 
takiben yüksek doz (30 mikromolar) ilaç verilerek, MCF-7/R6 ve MDA-MB-231/R2 
olarak adlandırılan sisplatine dirençli adenokarsinom hücre hattı oluşturulmuş ve 48 
saat sonunda 30 mikromolar ilaç verilerek apoptotik cevaba bakılmış ve kemoresistans 
durumu değerlendirilmiştir. 
Microarray çalışması için RNA izole edilmiş, analiz için 48000 gen probu 
(Illumina Human WG-6 BeadChip) kullanılmıştır. Gen ekspresyon verileri MATLAB 
2009 kullanılarak analiz edilmiş ve fark gösteren genler belirlenmiş ve ilaç resistant 
mekanizmalarını anlamak için proteomik analiz yapılmıştır. 
Verilerimiz ışığında ilaca dirençliliğin oluşmasını sağlayan GSTP1 ve ABCB6 
gibi markör genlerin transkripsiyonlarının MCF-7/R6 hücrelerinde arttığı görülmüştür. 
Kendiliğinden dirençli olan: MDA-MB-231 ve sonradan dirençli olan MCF-7/R6 
hücreleri NF-kappa-B yolağını aktive etmede benzer fakat MAPK yolağında ise farklı 
davranmışlardır. MCF-7/R6 hücreleri NF-kappa-B yolağını p50 alt birimi ile aktive 
etmekle birlikte Foxo3a transkripsiyon faktörünü çekirdeğe geçişini sağlamıştır. 
Hücre ölümü, Foxo ailesi ve MAPK seviyelerinden sorumlu olan genler, MCF-
7/R6 ve MDA-MB-231/R2 hücrelerinde protein seviyesinde de anlamlı bir şekilde 
değişmiştir. Transkripsiyon faktörü olan Foxo1 ve Foxo3a fosforilasyon seviyelerindeki 
değişim MCF-7/R6 hücrelerinin apoptosise olan rezistantını göstermektedir. Hücre 
döngüsü, tumor baskılayıcı, ve östrojen reseptör seviyelerinin MCF-7/R6  hücrelerinde 
değiştiği görülmüştür. 
Datalarımız açık olarak farklı rolleri olan kemoresistant mekanizmasına 
müteakip birçok protein ve yolak teşhis etmiştir. Bu bilgiler klinikte kullanılmak üzere 
doğrulanabilir. 
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1. INTRODUCTION 
 
 
 
 
Cancer arises from sequential changes that accumulate in the cell over time. One of 
the most implications is having combination of genetic, epigenetic and environmental 
changes which lead to transcriptional deregulation of genes, activation of different 
signal transduction pathways and altered gene expression. Cancer cells have some 
points in common; at the genetic level both loss and gain of function of genes, at the 
chromosomal level, abnormal chromosome number (aneuploidy, is universal in solid 
tumors), centrosome amplification, chromosome imbalance and loss of heterozygosity 
[26-28]. 
  
1.1 Breast Cancer 
 
Breast cancer is the most frequently seen cancer type among women and mortality 
rate is considerably high compared to other cancer types in both developing and 
developed countries. According to the World Health Organization statistics, nearly 1.2 
million people worldwide were diagnosed with breast cancer in 2007. The American 
Cancer Society estimates for women that 27% of new cancer cases resulted to death 
after attributing to invasive breast cancer in the United States in 2009. The probability 
of developing invasive breast cancer during a woman’s lifetime is approximately 1 in 8. 
Although there is a slight chance of common, approximately 1,700 cases of male breast 
cancer occur each year [1]. 
Breast cancer arises from the mutation of genes controlling cell growth, suppressing 
tumor development and repairing DNA. One of the genes that are mutated in breast 
cancer is BRCA1 and BRCA2. In addition to that, breast cancer developed by hormone 
deregulation such as progesterone and estrogen, both promotes breast tumorigenesis. In 
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breast cell cultures studies; strong correlation between progesterone receptors and cell 
growth is observed [35, 36]. 
In the long run, patients who are diagnosed with breast cancer begin to have distant 
metastasis. The prognosis still stays unclear. Breast cancer diagnosis level is crucial for 
patient. Stage IV patients have poor survival rate, whereas those with Stage I, usually 
have a normal life span. The involvement of axillary lymph nodes is an important 
indicator for overall survival in breast cancer. Nearly, 20 to 30% of node-negative 
patients relapse within 10 years, compared with about 70% of patients with axillary 
nodal involvement [64-68].  
Adjuvant chemotherapy is highly recommended to people who have breast cancer 
with node positive case, but for those who are node negative, adjuvant therapy create a 
risk of disease recurrence and death. 
 
1.1.1 Role of BRCA genes in breast cancer 
 
BRCA is a tumor suppressor gene that plays major role in breast cancer 
development. This gene somehow becomes disabled in progressing phase of the cancer.  
Two variants of BRCA do exist; BRCA1 and BRCA2. They have a wide range of 
function that is sensing DNA damage, repairing DNA, stabilizing chromosome. Once 
BRCA1 gene is mutated in breast cancer cells, double strand breaks that happen at basal 
state in G1 phase of the cell cycle cannot be removed and some part of the DNA 
sequences are bypassed during replication and lost or moved to another place in the 
chromosome where similar sequence is found. Moreover, when BRCA gene mutation 
happened, instead of “error free” DNA repairing mechanism that is homologues 
recombination (HR), “error prone” DNA repair mechanism that are non-homologous 
end joining (NHEJ),  and single-strand annealing (SSA)  become to be preferred as 
default [11]. 
Poly (ADP-ribose) polymerase-1 (PARP-1) is an enzyme that is involved in base 
excision repair which is an essential mechanism for single strand break (SSBs). 
Inhibition of PARP-1 leads to accumulation of SSBs and leading to Double strand 
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breaks (DSBs) and subsequently contributing BRCA gene mutation in breast cancer. 
This involvement inhibits HR (homologous recombination) type repair and NHJE (non-
homologous end joining) on the other hand, promotes SSA (Single-Strand Annealing) 
type repair mechanisms [15]. 
 
1.2 Chemotherapeutic resistance 
 
1.2.1 Anti cancer agent: Cisplatin 
Cisplatin is a chemotherapeutic drug used in the treatment of a variety of neoplasms 
and various cancers. Cisplatin induces DNA damage, inhibits DNA synthesis, 
suppresses RNA transcription, affects the cell cycle, and induces apoptosis in cancer 
cells by interfering with the resistance mechanism [155]. One proposed mechanism for 
major cisplatin activation is that, it becomes activated inside the cell by replacing two 
cis-chloro “leaving” groups with water and subsequently attaches to DNA with a 
covalent bond, results DNA adducts. Once it is activated, it becomes positively charged. 
The cytotoxicity of cisplatin is primarily comes from its interaction with nucleophilic 
N7-sites of purine bases which are common in all cells’ DNA and results DNA–protein 
and DNA–DNA interstrand and intrastrand crosslinks [156]. 
Cisplatin exerts its cytotoxic action through binding to DNA; mostly to guanine (G) 
and lesser extent to adenine (A) base [157]. Binding mostly occur on the same strand of 
DNA, even in between adjacent bases known as intrastrand adducts, interstrand adducts 
or crosslinks namely GpG 1,2 intrastrand (60-65%) and ApG 1,2 intrastrand (20-25%). 
In rare cases, same strand adducts can occur, namely GpXpG intrastrand crosslink 
where X represents any type of nucleotides (2%). Eventually 2% of adducts are G-G 
interstrand crosslinks that involves G on opposite strands [158]. In all cases two amine 
groups in cisplatin stay together with platinum. 
Generation of DNA adducts activates various signaling pathways in the cell, such as 
cell cycle arrest, programmed cell death /apoptosis if cell inadequately repaired [155]. 
By existence of this adducts; bending, winding, unwinding and transcription of DNA is 
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inhibited so; this is recognized by many cellular proteins that can also be involved in 
DNA repair mechanism [159]. 
 
1.2.2 Cisplatin Resistance 
Apoptosis effect which is resulting from cisplatin induced DNA damage can be 
attenuated by de novo established drug resistance mechanism. That mechanism creates 
limitations for cisplatin-based chemotherapy [160].  
Reasons for gaining resistance are; first, insufficient amount of drug is delivered to 
target cells; decreased accumulation or increased efflux of the drug may happen and 
second, Pt-DNA adducts may be repaired fast enough to impede apoptosis pathway 
[161, 162].  
Cisplatin resistance exists as a natural mechanism against drug called intrinsic 
resistance or can be gained during cycles of application along therapy by some effected 
organs with cancer such as ovarian, lung or colorectal. In other way, some cells always 
show hypersensitivity to cisplatin such as seen in testicular cancer cells. All in all, 
cisplatin resistance is cell type and tissue dependent. An excellent example to acquired 
resistance case occurs in ovarian cancer, which generally responds well to cisplatin-
based therapy at the beginning. Unfortunately, the initial response rate of cancer cells 
are up to 70% but not durable, and to the end of the therapy, decrease of survival rate 
down to 15–20% is seen because tumors become resistant to therapy [163]. 
1.2.2.1 Resistance through insufficient DNA binding 
Resistant tumor cell lines have less amount of Platinum accumulation than parental 
tumor cells [164]. Also upregulation or downregulation of certain proteins influence 
uptake or efflux of drug.  
In multidrug resistance mechanism, ATP dependent efflux pumps such as P-
glycoprotein’s are overexpressed; in cisplatin resistance, this pumps works for both 
decreasing uptake of drug and increasing efflux of drug [165]. Example to this efflux 
proteins are ATP-binding cassette protein subfamily and copper transporters; MDR1, 
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MRP2, MRP3 and ATP7A, ATP7B subsequently. ATPase genes are overexpressed in 
cisplatin resistant tumor cells [166]. ATP7B gene is used as a clinical marker of 
chemoresistance to cisplatin in ovarian cancer [167]. Copper transporter-1 (CTR1) role 
in cisplatin efflux has been shown clearly [168, 169].  
Cisplatin or carboplatin treatment causes cell to express more thiol-containing 
species such as glutathionine or metallothionein [Figure 1.1]. These two compounds are 
rich in methionine and cysteine and that leads to detoxification of drug because 
platinum can bind to sulphur strongly when compared to DNA. Cisplatin conjugated 
with glutathionine is catalyzed by glutathione S-transferases (GSTs) that makes 
compound more anionic so it can be pumped out to the cell more easily by ATP 
dependent glutathionine S-conjugate export (GS-X) pump namely, MRP1 and MRP2 
[126]. In translational studies, cisplatin or other DNA alkylating agent application to 
tumor biopsies resulted, glutathionine metabolic pathway modulation, de novo 
formation and inheritance [170]. Overexpression of low-molecular-weight thiol 
containing proteins or metallothioneins results heavy metal binding and detoxification 
so this leads to cisplatin resistance which is specific to cell types at many folds [171, 
172]. Resistance due to elevated GSH is acquired by overexpression of c-Jun gene and 
it is a reversible step [8]. 
 
Figure 1. 1: Cisplatin resistance during delivery of drug to the cell-prior to entering 
to nucleus (adapted from Kelland et al, 2007 ref 173). 
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1.2.2.2 Resistance mediated after DNA binding 
 
Cisplatin binding to DNA forms adducts that inhibit normal cellular functions, but 
cells can compensate this phenotype by activating DNA repair enzymes or removing 
these adducts. Testicular cancer cell has DNA repair deficiency by contrast in many 
resistant tumor cell lines have increased DNA repair capacity [174]. Once DNA is 
damaged, nearly 20 individual candidate proteins can recognize this adduct and bind 
physical distortions [175]. 
There are 4 major ways for DNA repairing; Nucleotide excision repair (NER), base 
excision repair (BER), mismatch repair (MMR) and double strand break repair. NER is 
the major pathway to remove cisplatin lesions from DNA, for the last years many 
groups have particular attention on NER endonuclease protein called ERCC1 (Excision 
repair cross complementing 1). ERCC1 forms heterodimer with Xeroderma 
Pigmentosum complementation group F (XPF), and make 5’ incision near to platinated 
DNA to repair. Resistant tumor cells have increased level of ERCC1 and XPF protein 
expression [176].  Downregulation of ERCC1 via siRNA showed enhanced cellular 
sensitivity against cisplatin and decreased level of action of NER for removing DNA 
lesions [177]. In patient who suffers from resistant ovarian cancer has increased ERCC1 
mRNA expression, nearly 2.6 folds [178]. MMR and HMG1, demonstrate greater 
preference for cisplatin adducts than for adducts induced by distinct platinum analogs 
[Figure 2]. Actual role of the DNA damage recognition proteins are; transducing DNA 
damage signal to downstream effectors, in this way appropriate action takes place but 
by means of HMG1 protein, case is different. It binds to the damaged DNA part but 
then shields this area from repair enzyme so it promotes cytotoxicity [179]. 
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Figure 1. 2: Regulated mechanisms for DNA adducts during cisplatin resistance-
mostly takes place inside the nucleus [adapted from Stordal et al 2007, ref 180]. 
 
Once the cells are treated with cisplatin, RAD51 foci formation, that show DNA 
damage is revived by homologues recombination, nearly diminished in BRCA1 mutant 
cells. Because of cells that cannot restore DNA damages, they are led to apoptosis [3]. 
BRCA1 gene transfection assays showed that; reconstitution of the gene to normal level 
or to wild type level, make cells resistant to cisplatin [4]. 
The most realistic breast cancer mouse model was achieved with deletion of both 
p53
k14cre
 gene and BRCA1
k14cre
 gene together only in epithelial cells; it is called as 
Jonkers mouse [5]. When Jonkers mouse is treated with anti-cancer agent; cisplatin, 
docetaxel and doxorubicin, tumors never developed drug resistance but except 
doxorubicin. In doxorubicin resistant tumors, gene expression study showed that; 
Mdr1a and Mdr1b genes upregulated. That result was documented by increased 
transportation of doxorubicin out of doxorubicin resistant tumors [6]. Cells were also 
initially sensitive to cisplatin but after treatment of tumor with cisplatin, cancer 
recurred. Hypothesis for cisplatin resistance cells to survive: cisplatin damages DNA, 
surviving cells against cisplatin treatment has to develop ability to produce repair 
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proteins/ or survival proteins to prepare itself for the next insult. Continuous exposure 
of tumor to cisplatin selected only cisplatin resistant stem cell and these cells become 
aggressive after some time of treatment and began to invade [7]. 
 
Patel et al. established breast cancer cell line that is over-expressing IκB, and found 
that these mutant cells, when compared to parental cells, express fewer anti-apoptotic 
proteins and are more sensitive to taxol induced apoptosis [181]. Thus, NF- κB -
regulated genes seem to have effect on resistance against chemotherapy via the 
expression of anti-apoptotic proteins. 
 
Drug resistant and metastatic cancer cells behave in similar way. By means of 
resistance and enhanced invasiveness, both type of cells show great analogy [153]. 
 
1.3 Nuclear Factor kappa (NF-κB) 
 
NF-κB was discovered in the nuclei of mature B lymphocytes as a transcription 
factor that binds to 10 base pairs long sequence on DNA in the kappa immunoglobulin 
light-chain enhancer by a group of scientist Sen et al in 1986 [69]. Inappropriate NF κB 
expression is known to be the reason of coupling one transcription factor to aberrant, 
upstream signaling pathways affecting specific DNA promoter(s) involved in 
inflammation, cell survival, oncologic transformation or apoptosis because NF κB is a 
pleiotropic transcription factor.  [144].  
 
1.3.1 Canonical and non-canonical NF-κB pathway  
The NF-κB/Rel family comprised of 5 subunits; p65 (RelA), p50/p105 (NFκB1), 
p52/p100 (NFκB2), c-rel and RelB. NF-κB1 is derived from proteolytic processing of 
its precursor p105 and liberates p50. NF-κB2 is derived from proteolytic processing of 
its precursor p100 and liberates p52. RelA, RelB, c-rel proto-oncogene products contain 
transcriptional activation domains on the other hand p50 and p52 do not [49, 145]. 
These 3 members, v-rel oncogene and the drosophila morphogen dorsal-encoded protein 
also belong to Rel family of protein [49, 145]. These subunits are identified and cloned 
9 
 
in mammalian cells [70, 71]. All NF-κB proteins involve 300-amino acid N-terminal 
Rel Homology Domain (RHD) that enables them to bind DNA and IκB also make 
dimmers with Rel family proteins and target to nucleus [72, 144].   
NF-κB can be activated by either canonical or non-canonical pathway [reviewed in 
reference (144,146)].  
In canonical pathway; there is activation and degradation of IKK and IκB 
subsequently. IκB Kinase (IKK) initiates degradation of IκB by phosphorylating it from 
2 conserved serines in the N-terminal. Phosphorylated IκB becomes dissociated from 
NF-κB, unmasking the NLS. Phosphorylation also results in IκB ubiquitination and 
targeting to the proteasome to degrade rapidly by the 26S proteasome [79, 80]. This lets 
NF-κB to translocate to the nucleus and activate the transcription process [Figure 1.3A].  
In non-canonical pathway; B cell-activating factor receptor (BAFF), CD40, and the 
lymphotoxin-βκ-receptor (LTβR) stimulated NF-κB-inducing kinase (NIK) and IKKα. 
This induction results with processing of p100 to p52 and facilitating the nuclear 
translocation of RelB/p52 dimmers into the nucleus as showed in Figure 1.3B [146]. 
Compared to p52 whose proteolytic processing is tightly regulated, the proteolysis of 
the precursor protein p105 to p50 is constitutive in unstimulated cells [144]. Increasing 
evidence of dysregulated NF-κB-associated pathways in various human breast cancer 
cell lines and primary tumors shows that NF-κB has an important role in neoplastic 
transformation [147]. Abnormal proliferation and branching of the mammary 
epithelium is observed in IκBα gene knock out mouse [148]. Inhibition of NF-κB 
restores the sensitivity of endocrine resistant breast cancer to tamoxifen [149]. P50/p65 
is the major increased NF-κB dimmer in breast cancer cell lines [150]. Zhou et al. 
claimed that the activation of the p50 homodimer might be used as a prognostic marker 
in a subset of ER positive breast cancer patients [149, 151]. 
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Figure 1. 3: Pathway of NF-κB activation.  A: Canonical pathway B: Non-
canonical pathway. [Retrieved from: www.abcam.com]. 
Before activation of NF-κB subunits, they can undergo either homo- or 
heterodimerization in the cytoplasm in this way that binds to promoter regions which is 
decameric sequences of both cellular and viral genes [45-48, 72].  
 
1.3.2 IκB family of proteins 
In resting cells, NF-κB dimmers are sequestered in the cytoplasm in a passive form 
via association with IκB (inhibitor of κB) family. The IκB family involves structurally 
related proteins defined as IκB-α, IκB-β, IκB-γ, IκB-є, IκB-δ, p105, p100, bcl3, among 
which IκB-α is the most abundant inhibitor protein for NF-κB [72–75]. These proteins 
characteristically include a stretch of five to seven ankyrin repeat domains concealing 
the nuclear localization sequences within the RHD of dimeric NF-κB. Activation of the 
NF-κB signaling cascade results in complete degradation of IκB by the 26S proteasome, 
or partial degradation of the carboxyl termini of p105 and p100 precursors, via cleavage 
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of ankyrin domains revealing the nuclear localization sequences of NF-κB proteins [72]. 
These modification processes of IκB and p105/p100 enable NF-κB to translocate into 
nucleus in a dimeric form, thereby affecting target gene expression [76]. 
1.3.3 IKK family of proteins 
When cells are stimulated with proper ligand, signaling pathways of NF-κB 
converge on a family of proteins termed IκB kinase (IKK) kinases. IKK contains 
members of the mitogen-activated protein kinase kinase (MAPKK) family, such as NF-
κB-inducing kinase (NIK) and mitogen-activated protein kinase/ERK kinase kinase 1 
(MEKK1), 2, and 3 [77]. These proteins activate IκB kinase (IKK) complex, a 
heterotrimeric cytoplasmic protein including two catalytic subunits, IKK-α (IKK1) and 
IKK-β (IKK2), and a structural component termed IKK–γ (NEMO) [78]. IKK–α and 
IKK–β subunits are catalytically active and the IKK–γ subunit serves a regulatory 
function.  
1.3.4 Mechanism of NF-κB Specificity 
NF-κB has been connected to various metabolism processes and diseases, including 
developmental processes, inflammation and immune responses, cell growth, cancer, 
atherosclerosis, AIDS, diabetes, and the expression of certain viral genes [81]. 
Interestingly, NF-κB is induced by more than 150 different extracellular stimuli, 
enclosure but not limited to bacteria, virus, interleukins, growth factors, 
chemotherapeutic agents, and various stress stimuli (physiological, physical, and 
oxidative) [82]. Similarly, the activation of NF-κB promotes the expression of more 
than 150 target genes; Figure 1.4 illustrates particular genes [82].  
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Figure 1. 4: Brief list of NF-κB target genes 
 
The aggregation of NF-κB inducers and its target genes suggests that NF-κB may 
function as a “central mediator of the human stress response” [82]. For NF-κB, the 
specificity may depend on the cell type targeted; not all cell types respond equally to a 
given stimulus, either because they devoid of the cognate receptor or because they lack 
the required signal transduction molecules [77]. NF-κB has a combinatorial regulation 
of target genes. Sometimes increment of NF-κB only is not enough for target gene 
expression it also requires other transcription factors. In this way NF-κB becomes very 
specific to the events and can have opportunity to merge with other signaling pathways 
[82].  
 
1.3.5 Effect of NF-κB on breast cancer 
Several studies were conducted on effect of NF-κB on breast cancer development 
and progression. ER-negative cell lines, MDA-MB-231, in general, contained elevated 
levels of AP-1 and NF-κB compared to MCF-7 cells at constitutional level [55]. NF-κB 
physically associates with transcription factor AP-1 and can indirectly increase 
expression of AP-1 regulated genes [44]. The NF-κB –DNA complex in ER-negative 
cell lines is comprised of the RelA subunit of NF-κB, confirmed by super-shift assay. 
Nakshatri et al. reported that; RelA band but not c-Rel antibody band super-shifted [55]. 
Estrogen receptor (ER) interferes with; constitutional transcriptional activation function 
of NF- κB and binding of it to decameric promoters in MDA-MB-231cells [55]. A 
posttranslational modification of NF- κB is crucial for optimal transcriptional activation 
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through NF- κB, and such modification takes place merely in ER-negative cell lines 
[55]. There is a parallel correlation between constitutional activation of NF- κB and 
DNA binding activity; on the other hand there is an inverse relationship between NF- 
κB activation and estrogen receptor (ER) presence status in breast cancer cells [55]. 
As the cancer cell become more vigorous and cell growth become deregulated, in 
parallel NF- κB is hyper-activated. Upon switching from inducible to constitutive NF- 
κB activation, cell become resistant to apoptosis and become to secrete chemokines, 
cytokine and growth factors  and also have tendency to metastasize [39, 40]. Aberrant 
regulation of NF- κB modulates the response against to the cytotoxic effects of TNF-
induced or radiation-induced apoptosis [61]. The proliferation of both normal and 
transformed rat Mammary Epithelial Cells (MEC) was accompanied by increased 
DNA-binding activity of the NF-κB p50 homodimer [143]. NF-κB down regulation is 
probably required for TP53-dependent apoptosis [62]. Because p53 is known to trigger 
apoptosis in cells with damaged DNA and conversely NF- κB promotes the survival of 
these mutated cells and leads to neoplastic transformation [152]. 
Target gene activation of NF-κB is not only dependent upon nuclear translocation 
but also dependent on tyrosine kinase transactivation process. In addition to that, 
increased level of expression of NF- κB does not have to be finalized with increased 
DNA binding [56]. NF-κB regulates the expression of many genes including; integrin-
αv which is required for metastatic protein activation MMP2 [37, 38] and many cell 
surface receptors, among them the Mdr-1 gene, which encodes the multiple drug 
resistance mediator [154]. 
 
Treatment of cancer cells with Cisplatin result in degradation of IκB proteins, thus 
releasing the bound NF-κB, which translocates to the nucleus and upregulates target 
gene expression [50]. Taken together, these results suggest that the NF- κB system plays 
a critical role in balancing survival and death of mammary epithelia, and that aberrant 
NF- κB signaling is responsible, relatively, for breast cancer progression.  
 
 
 
14 
 
 
1.4 MAP kinases 
 
Mitogen-activated protein kinases ubiquitous and highly complex intracellular 
signaling network that is ultimately responsible for regulating gene expression in 
response to a variety of extracellular stimuli. MAPK pathways activate diverse 
fundamental processes: metabolism, survival, mitosis and apoptosis [197, 198]. In 
mammalians, MAPKs are categorized to 3 groups according to function: stress-
activated protein kinase/c-Jun N-terminal kinases (SAPK/JNKs 1, 2 and 3), p38 
(isoforms a, b, c and d) and extracellular signal-regulated kinases (ERKs 1, 2, 3, 4 and 
5). 
 
Each family of MAPKs is consisting of a set of three evolutionary conserved, 
consecutively acting kinases: MAPKK kinases (MAPKKKs or MAP3K), MAPK 
kinases (MAPKKs or MAP2K) and MAPKs. The MAP3K is a serin–threonine kinase. 
It is a contact molecule that senses active signals from the membrane-spanning 
receptors, then phosphorylates thus activates its downstream substrate which is 
MAP2K. MAP2K is an intermediate kinase with dual-specificity. It phosphorylates 
threonine and tyrosine residues on MAPKs. MAPKs are also serine-threonine kinase 
which phosphorylates and enables cytoplasmic proteins to transmit the signal from 
cytoplasm to the nucleus [199]. 
 
SAPK/JNK and p38 are activated throughout stress and inflammation evoked by a 
variety of physical, chemical and biological stress stimuli whereas ERK1/2 cascade is 
mostly activated by being exposed to growth factors. Despite differences of stimuli that 
activates them, these pathways merge and crosstalk [198]. MAPKs are induced by 
consequential stimulation of uppermost kinase cascade [197, 198]. 
 
Wide range of substrates are phosphorylated by MAPK such as; phospholipases, 
cytoskeletal proteins, several protein kinases (MAPK-activated protein kinases; MKs) 
and transcription factors in this way controls expression of different genes [Figure 1.5]. 
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SAPK/JNK (stress activated protein kinase/Jun N-terminal kinase) as the name 
implies, is activated through cellular stress. It is a serin–threonine kinase which 
phosphorylates the amino-terminal domain of the Jun transcription factor. It has a 
resulting function as; cell survival, oncogenic transformation, growth, differentiation 
and cell death. SAPK/JNK is encoded by three separate genes; jnk1, jnk2 and jnk3. 
Alternative splice version of them creates at least ten isoforms with alternating substrate 
preferences. The substrates of SAPK/JNK are c-Jun, JunB, JunD and the related ATF2 
transcription factor, as well as p53, NFAT4, NF-ATc1, HSF-1, STAT3 and Elk-1 [197, 
200]. PI3-K/Akt signaling survival pathway inhibits cDDP-induced SAPK/JNK and p38 
activation by phosphorylating ASK1 [122]. 
 
 
Figure 1. 5: MAPK signaling pathway 
 
In mammalian cells, p38 is stimulated throughout environmental stress and 
inflammatory cytokines, less by mitogens. Most activators which induce p38 also 
stimulates SAPK/JNK cascade simultaneously. The p38 substrates are: cytosolic 
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phospholipase A2, the microtubule-associated protein Tau, transcription factors ATF1-2, 
MEF2A, Sap-1, Elk-1, NF-κB, Ets-1 and p53, and several MAPK-activated protein 
kinases (MKs) [198]. 
ERK1/2, are involved in cell proliferation and activated through growth factors, 
serum, phorbol esters, ligand of heterotrimeric G protein-coupled receptors, cytokines, 
osmotic stress, and by microtubule disorganization [198,199]. ERK1/2 substrates are; 
CD120a, Syk and calnexin, SRC-1, Pax6, NF-AT, Elk-1, MEF2, c-Fos, c-Myc, STAT3, 
some cytoskeletal proteins and several MKs [198,199].  
Cisplatin given to the cell activates ras mediated transduction pathway. Ras 
activates a complex signaling network of MAP3K and ERK1/2 leading to cell death in 
breast carcinoma cells. Members of ras also involved in regulation of p38 [201, 202]. 
Inhibition of ERK and SAPK/JNK sensitizes human ovarian papillary adenocarcinoma 
cells (Caov-3) and ovarian cancer cells (A2780) to cisplatin induced cell death [123].  
 
One of the common crucial downstream substrate of SAPK/JNK and ERK 
activation cascade is activator protein-1 (AP-1), AP-1 components (including ATF2 and 
c-Jun), and transactivation sites of AP-1 that might be required for DNA repair 
mechanism. AP-1 provides molecular basis for enhanced DNA repair [121]. 
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1.5 Foxo family 
 
FOXO family of proteins function as transcriptional factors that interact with the 
core consensus DNA sequence GTAAA(C/T)A to modulate target gene expression 
[183]. The mammalian FOXO family of transcription factors are; FOXO1, FOXO3a, 
FOXO4 and FOXO6. These are major substrates of the protein kinases PKB (protein 
kinase B) and SGK (serum and glucocorticoid-induced protein kinase), which are part 
of PI3K signaling pathway [183–185]. The newly identified FOXO member, FOXO6, 
always stays in the nucleus due to lack of C-terminal PKB consensus phosphorylation 
motif [186]. 
 
 
Figure 1. 6: Target genes of FOXO [Adapted from Host et al., ref 9] 
 
FOXO transcription factors are thought to be as tumor suppressor genes because 
they mediate cell cycle arrest, DNA repair and apoptosis [183]. Low level of FOXO in 
the cell may result tumor development and expansion. The target genes of FOXO are 
involved in; cell cycle progression (p27
Kip1
, p130 (RB2), cyclin D1/2 and Bcl-6 (B-cell 
lymphocytic leukemia proto-oncogene 6)) and apoptosis (Bim, Fas ligand, TRAIL 
(tumor-necrosis-factor-related apoptosis inducing ligand) and Bcl-XL) as showed in 
Figure-6 [183,187-189]. PKB phosphorylates FOXOs and this results sequestration of 
FOXO in the cytoplasm and inability to activate cell death inducing genes due to 
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degradation of FOXO therefore as a result cell survival is seen [187-189]. 
Phosphorylated FOXOs are retained in the cytoplasm by 14-3-3 chaperone. JNK can 
phosphorylate 14-3-3 in this way FOXO relocates into nucleus [192]. 
 
In neurons, FOXO3a triggers cell death circuitously by activating the expression of 
Fas Ligand, which stimulates programmed cell death through the death receptor 
pathway [183]. 
FOXO3a increase the expression of the antioxidant enzymes, mitochondrial 
MnSOD (manganese superoxide dismutase) and catalase, which are scavengers of 
oxygen-free radicals) and results oxidative resistance, another target is multidrug 
resistance transporter genes (MDR1, ABCB1) [190]. 
 
FOXO modifications is not limited only to phosphorylation, it can also be acetylated 
by SIRTs (Sirtuins) in this way FOXO is activated and resulting effect of activation  is 
being away from cell death and cell becomes stress resistance in humans (Figure-7) 
[193]. 
 
FOXO1 gene expression level is enhanced in paclitaxel-resistant and cisplatin-
resistant ovarian cancer cells and cells are sensitized to drugs when FOXO1 is silenced 
by siRNA technology [195]. Knocking out studies on FOXO1 shows embryonic 
lethality whereas FOXO3a and FOXO4 not [196]. 
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Figure 1. 7: FOXO modifications and different consequences 
 
β-catenin, a transcription factor that plays a major role in development and tissue 
self-renewal, physically interact with FOXO proteins and enhances their transcriptional 
activity [194].  
PTEN (phosphatase and tensin homologue deleted on chromosome 10) is an 
antagonist of PI3K pathway and somatic deletion or mutation elucidates human tumours 
at a large ratio 12-60% [182]. PTEN mutation leads to constitutive activation of PI3K 
and a resultant loss of FOXO1 and FOXO3a [191]. 
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1.6 p53 gene 
 
P53 is transcription factor which have a central role in tumor suppression by 
inducing apoptosis [16, 17] or promoting normal cell growth and regulate cell cycle [24, 
25]. TP53 gene is mutant or inactivated in 50% case of human tumors [58]. Most of the 
breast cancer cells have high grade TP53 gene mutation or modulation and this enables 
gene to inactivate [12, 18]. MCF-7 human breast cancer cell line harbors wild-type p53 
gene in the genome and functionalized p53 protein is located at the nucleus [19]. In 
breast cancer cells, high degree of mutation rate is seen in p53 gene and this reasons to 
high proliferation rate which is expected in view of the role of p53 as a negative 
regulator of cell proliferation [20-22]. 
The level of p53 protein is highly sensitive to hormones such as progesterone 
because progesterone induces cells to differentiate rather than growth and p53 protein 
level decreases as the level of exposed progesterone increases in MCF-7 cells [13].  
In mammary epithelial cell model that lacks p53 gene, tumorigenesis, chromosome 
instability (aneuploidy), and centrosome amplification is seen [23, 29-31]. In 
developmental phase, p53 null mammary epithelial cells show normal development but 
high rate of tumorigenesis incidence. The mammary tumors that lacks p53 gene 
increased their DNA content by the hormone stimulation; especially progesterone rather 
than estrogen, it only expanded tumor rate [32-34]. DNA repair ability is not directly 
related to TP53 activity at G1/S-phase [59, 60].  
ATM and ATR are two kinases that regulates and stabilize the p53. Cisplatin 
preferentially activates ATR kinase then it phosphorylates p53 from at serine-15 and 
activate [119, 120]. MAPK is also involved in p53 phosphorylation and inhibition of the 
MEK–ERK pathway leads to cisplatin resistance [117]. Akt also phosphorylates Mdm2 
onco-protein that is inhibitor of p53 in this way drug resistance phenotype is achieved 
[118]. 
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1.7 p21 gene 
 
P21 is a cell cycle progression inhibitor whose expression is controlled by the p53 
tumor suppressor gene [97]. P21 have a role in cellular differentiation, senescence and 
inhibition of apoptosis [98, 99]. Cyclins and CDKs bind to p21 through the consensus 
site CRRL (p21 amino acids [aa] 18 to 21) at the N-terminal end, and this motif is 
required for inhibition of cell cycle progression [96]. 
 
 
Figure 1. 8: p21 and p53 pathway 
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Interaction of Cyclin-CDK with p21 induces association of this complex with 
PCNA which stimulates DNA polymerase δ and ε. These polymerases enable DNA to 
replicate at high fidelity and conduct excision repair [94, 95]. 
Function of p21 is dependent on its subcellular localization. Akt has been reported 
to phosphorylate p21 and p21 retains in the cytoplasm whereas cytoplasmic retention of 
p21 in HER-2/neu-overexpressing cells results loss of cell cycle inhibition and gain of 
apoptosis inhibitory activity [90, 91]. It has also been reported that upon differentiation 
status of U937 cells into monocytes, p21 translocates from the nucleus to the cytoplasm 
and rescues cell death [83]. Furthermore, p21 mutant that lacks nuclear localization 
signal sequence did not induce cell cycle arrest or monocytic differentiation [90]. 
Subsequent exposure to alkylating agents, p21 localizes into nucleus and in addition to 
that promotes cell cycle arrest and prevent S-phase progression, p21 also colocalizes 
with PCNA to instigate nucleotide excision repair [85, 86]. 
 
1.8 Wnt Signaling Pathway 
 
The Wnt signaling pathway is substantial for cell as having a role in cell 
differentiation and proliferation, cell movement and polarity, and for maintenance of 
self-renewal in hematopoietic stem cells [reviewed in ref. 84], and defects in this 
pathway are inclusive of the pathogenesis of several tumor types, including breast 
cancer [reviewed in refs. 92 and 93].  
Wnt signals are transduced through two distinct pathways, the canonical and the 
non-canonical [84] substantially due to the fact that Wnt is a family of closely related, 
secreted glycoproteins with at least 19 members that can bind to different cell surface 
receptors with different combinations that eventually determine which specific pathway 
is activated [57, 63]. 
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Figure 1. 9: Wnt pathway 
 
On the canonical pathway, secreted Wnt ligands are transduced through the Frizzled 
(FRZ) family of transmembrane receptors and the low-density lipoprotein receptor-
related protein (LRP5/6) co-receptor to eventually stimulate β-catenin, the important 
transcription regulator of growth-promoting genes. There are numerous positive and 
negative regulators of this pathway, and loss of negative regulation, which activates 
constitutive signaling and growth, is an important contributor to tumor development 
[87-89]. Binding of Wnt to Frizzled is followed by Dishevelled (Dvl) aggregates 
assembling a scaffold-like structure at the plasma membrane [54]. This triggers 
formation of clusters of LRP5/6 that are then phosphorylated by casein kinase I (CKIγ). 
On the following, Axin, in complex with glycogen synthase kinase 3 β (GSK-3β) and 
the associated APC proteins, binds to complete the LRP signalosome [54]. Thus the 
activity of GSK-3β is inhibited and β -catenin aggregated in the cytoplasm [53]. β -
catenin is then able to translocate into the nucleus where it activates T-cell 
factor/lymphoid enhancer factor (TCF/LEF) transcription factors that subsequently 
activate expression of a number of genes (in part by displacing Groucho and HDAC) 
including those involved in epithelial-to-mesenchymal transition and cell proliferation 
such as c-myc, c-jun, cyclin D1 and CD44 [Figure 1.9B]. In the absence of Wnt 
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binding, complex of GSK-3β along with CKIα, APC and Axin, phosphorylates β -
catenin, targeting it for proteolytic degradation [Figure 1.9A]. However, Lee et al. 
recently demonstrated that Dvl overexpression compensate absence of Wnt ligand and 
promote transcriptional activation of TCF/LEF-responsive genes, reporting that if the 
concentration of Dvl is high enough to support self-association near the plasma 
membrane, LRP5/6 can assemble and form the LRP signalosome even in the absence of 
a Wnt ligand [52]. Wnt has an important contribution to tumorigenesis in breast cancer 
[87]. 
 
1.9 NFAT pathway 
 
The nuclear factor of activated T cells (NFAT) signaling axis is a vertebrate-specific 
pathway important for a variety of cellular functions such as; development and 
activation of lymphocytes and differentiation of cardiac muscle cells [51, 44]. In the 
canonical pathway which was firstly elucidated in immune cells, NFAT is induced as a 
result of calcium efflux from endoplasmic reticulum stores and from the extracellular 
environment through the activation of store-operated channels in the plasma membrane. 
In the steady-state, NFAT is hyper-phosphorylated and remains in the cytoplasm. 
Subsequent to cell stimulation and calcium release, NFAT is dephosphorylated by the 
phosphatase calcineurin and translocates to the nucleus where it work together with 
other factors and co-activators to provoke de novo gene transcription. 
 NFAT1 (also known as NFATc2 and NFATp) null mice show hyperproliferation of 
splenic B and T cells due to absence of FasL expression and therefore do not undergo 
cell death [43].  
NFAT2 (also known as NFATc1 and NFATc) null mice show defects in 
development of heart valve morphogenesis related to an abnormal cardiac septum, 
providing evidence for an irrevocable role for NFAT2 in cardiac development [42].  
NFAT4 (also known as NFATc3 and NFATx) null mice confer abnormal 
development of myofibers as well as having reduced thymocyte numbers due to 
suppression of Bcl-2 expression [41].  
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Constitutively active NFAT1 stimulated cell to halt cell cycle and undergo apoptosis 
and inhibited RasV12 induced transformation, whereas constitutively active NFAT2 
increased cell proliferation and transformation. NFAT1 null mice are more sensitive to 
chemically-induced carcinogenesis [14]. In human breast epithelial cells, the non-
canonical Wnt ligand, Wnt5a which is known to inhibit metastatic progression blocks 
NFAT activation coincident with attenuated migration by a mechanism that depends in 
part on the binding of CK1 [2]. 
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2. PURPOSE 
 
 
 
 
Cells confer resistant to drug either intrinsically or extrinsically. Extrinsic 
resistance also called acquired resistance. Continuous and periodic treatment of cells 
with the same drug either with increasing amount or with the same dose of drug began 
to be ineffective against cancer cells. Cells adapt to this drug and start to provide a new 
mechanism to escape apoptosis such as enhanced DNA repair mechanisms, survival 
pathway activation and for breast cancer cells; ER positive (+) cells began to grow 
without needing estrogen. Resistant cells outline an obstacle for treatment of cancer.  
This is the first study reporting, de novo established cisplatin resistant cell line of 
MCF-7 and MDA-MB-231. Research reports on drug resistant mechanism is always 
emanated from other cell lines especially from ovarian cancer cell.  Cisplatin resistance 
mechanism in MCF-7 is unexplored on the other hand, ER resistance mechanism that 
means cell become to grow without needing estrogen receptor and estrogen, paclitaxel 
and tamoxifen resistance are well-defined. 
For this purpose, after establishment of de novo cisplatin resistant cell line, we 
wanted to investigate differentially expressed genes between control MCF-7 and MCF-
7/R6 cell line by using microarray. And for further investigation of which signaling 
pathways become activated in cisplatin resistant breast cancer cell line; total protein 
levels of MCF-7/R6, MDA-MB-231/R2 and parental cells of both are checked with 
specific antibodies. For further study of proteins, activation of some transcription 
factors is demanded to check through nuclear protein isolation. 
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3. MATERIALS 
 
 
 
3.1 Chemicals 
All chemicals that are used are listed in Appendix A. 
3.2 Antibodies 
All Antibodies that are used are listed in Appendix B. 
3.3 Molecular biology and cell culture 
Molecular biology kits used for immunoblotting experiments and cell culture 
materials are listed in Appendix C. 
3.4 Equipments 
Equipment that is used for general laboratory procedures are listed in 
Appendix D. 
3.5 Buffers and Solutions 
 
3.5.1 Buffers and Solutions for Cell death assays 
 
Annexin V-FITC incubation buffer: 10 mM HEPES, 140 mM NaCl and 2.5 mM 
CaCl2 were dissolved in 500 ml of ddH2O. The buffer is kept at 4
o
C. 
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3.5.2 Buffers and Solutions for protein isolation 
3.5.2.1 Total protein isolation 
 
Cell Lysis Buffer: 150 mM NaCl, 1% NP-40 and 50 mM Tris dissolved in 
ddH2O; afterwards pH is adjusted to 8.0 by using 5M HCl solution. The buffer was 
stored at 4
0
C.  
Complete cell lysis buffer: was prepared by adding 1X protease inhibitors, 1X 
phosphatase inhibitors and 0.5 M PMSF freshly to cell lysis buffer. 
10X PBS (Phosphate Buffered Saline): 80 g NaCl, 2.0 g KCl, 14.4 g Na2HPO4 
and 2.4 g KH2PO4 were dissolved in 1L of ddH2O and pH is adjusted to 7.4. 
 
3.5.2.2. Cytoplasmic and Nuclear protein fractionation 
 
T1 buffer: 10mM HEPES-KOH (pH:7.9), 2mM MgCl2.6H2O, 0.1mM EDTA, 
10mM KCl, 1% NP-40 and freshly added DTT, 0.5mM PMSF, complete protease and 
phosphatase inhibitor (Roche).  
T2 buffer: 20 mM HEPES-KOH (pH:7.9), 1.5 mM MgCl2, 0,2 mM EDTA, 650 
mM NaCl, glycerol (25%,v/v) with freshly added 1 mM of DTT, 0,5 mM of PMSF, 1X 
protease and phosphatase inhibitors. 
 
3.5.2.3 Buffers and Solutions for SDS polyacrylamide gel electrophoresis 
 
1.5 M Tris-HCl pH 8.8: 1.5 M Tris was dissolved in ddH2O and pH was adjusted 
at 8.8 with HCl. 
0.5M Tris-HCl pH 6.8: 0.5M Tris was dissolved in ddH2O and pH was adjusted 
at 6.8 with HCl. 
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3.5.2.4 Buffers and Solutions of Immunoblotting 
 
1X PBS-Tween20 (PBS-T): 10X PBS was diluted to 1X, 0.2% Tween20 was 
added to 1X PBS. 
10X Running Buffer: 30.3 g Tris, 144.1 g Glycine, 10 g SDS were dissolved in 
1L of ddH2O and pH was adjusted at 8.3. 
 
10X Transfer Buffer (TB): 30.3 g Tris and 144 g Glycine were dissolved in 1L 
of ddH2O. 
1X Transfer Buffer: Before conducting transfer step, 1X TB is freshly prepared. 
20% (v/v) methanol was added into 1X TB and the remaining volume was completed 
with ddH2O. 
Blocking Solution: 0.05% (w/v) dried milk powder was dissolved in 1X PBS-T.  
Stripping Buffer: 2.5 mM Tris-HCl and 2% SDS (w/v) were dissolved in 500 ml 
ddH2O and pH was adjusted to 6.7. 352.1 μl of β-mercaptoethanol was added for 50 ml 
of solution prior to use. 
 
3.5.3 Buffers for RNA integration test 
 
10X MOPS buffer: 0.4 M MOPS, pH 7.0, 0.1 M sodium acetate, 0.01 M EDTA 
was dissolved in ddH2O. 
 
3.5.4 EMSA buffers 
 
T4 polynucleotide kinase (Promega): T4 Polynucleotide Kinase catalyzes the 
transfer of the γ-phosphate from ATP to the 5´-terminus of polynucleotides or to 
mononucleotides bearing a 5´-hydroxyl group. The enzyme, purified from recombinant 
E. coli, may be used to phosphorylate DNA and synthetic oligonucleotides prior to 
subsequent manipulations such as EMSA. 
T4 Storage buffer: 20mM Tris-HCl (pH 7.5), 25mM KCl, 2mM DTT, 0.1mM 
EDTA, 0.1μM ATP and 50% (v/v) glycerol. 
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T4 10X Reaction Buffer: 700mM Tris-HCl (pH 7.6 at 25°C), 100mM MgCl2, 
and 50mM DTT. 
Gel shift binding buffer: 20 mM HEPES/KOH, [pH 7.9], 5 mM EDTA, 25% 
glycerol (v/v), 2.5 mM MgCl2.6H2O, 0.5 M KCl and freshly added, 10 mM DTT, final 
volume 10 µl. 
Binding Reaction mix: ddH2O, 4 µl binding buffer, 3.45 glycerol, 1 µl of BSA, 
1.5 µl of poly [dI-dC], 5-8 µl nuclear protein extract and 1 µl γ-32P-labeled NF-κB and 
Foxo3a probe . 
10X TBE: 108 g Tris base, 55g Boric acid, and 40 ml of 0.5M EDTA (pH 8.0) 
in 1L dH2O. 
EMSA loading dye: 30% (v/v) glycerol, 0.25% (w/v) bromophenol blue   
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4. METHODS 
 
 
 
 
4.1 Cell Culture 
 
The MCF-7 human adenocarcinoma breast cancer cell lines were obtained from 
the American Type Culture Collection (HTB-22, ATCC, USA) and MDA-MB-231 cells 
(HTB- 
26, ATCC) and  were maintained in Dulbecco's Modified Eagle Medium (Pan 
Biotech, Germany) supplemented with 10% Fetal Bovine Serum (Pan Biotech, 
Germany), 2 mM glutamine (Pan Biotech, Germany), 50 U/ml penicillin, 50µg 
streptomycin (Pan Biotech, Germany). All cells were incubated in a humidified 
atmosphere of 37
o
C and 5% CO2 in T75 cm
2
 flasks as an attached layer. MCF-7 drug-
resistant (MCF-7/ Cisplatin) cell line was established by 2 step selection procedure after 
prolonged (> 6 months) treatment of cisplatin. These cyclic treatments were repeated for 
6 months. MCF-7 cells were pretreated with 1μM Cisplatin (Sigma) for 4 days. 
Afterward, cells were treated with 30μM (Sigma) Cisplatin for 4 hours. For recovering 
phase (approximately 2 weeks), medium was replaced with fresh drug-free complete 
medium. Surviving populations of parent MCF-7 cells were used for cell death analysis 
by performing Flow Cytometry (BD Biosciences). 
 When cells are grown to confluency, subculturing to new passage numbers is 
done with 0.05 % Trypsin/EDTA solution. As soon as cells are detached, in 37
o
C 
incubator, medium containing 10% serum is added to inhibit further activity of trypsin 
that might damage cells. Cells are counted with hemacytometer by using the following 
formula; 
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Cell suspensions are passaged to new flask and wells in appropriate seeding 
densities as follows; 
 
Table 3. 1: Seeding density. The number* of cells on a confluent plate, dish or flask 
will vary with cell type 
 
Dimension Seeding 
Density 
Cells at 
Confluency* 
Trypsin Growth 
Medium 
6-well    0.3 x 106 1.1 x 106 2 3-5 ml 
100mm 1.7 x 106 6.8 x 106 8 10 ml 
25cm
2 0.7 x 106 2.8 x 106 3 3-5 ml 
75cm
2 2.1 x 106 8.5 x 106 5 8-15 ml 
 
 
4.2 Cryopreservation 
 
 
For long-term storage, cells are cryopreserved as follows; cells are trypsinized, 
spinned down at 13.400 rpm for 30 seconds and washed with 1X sterile PBS. Cells are 
resuspended in freezing medium which contains 10% tissue culture grade sterile DMSO 
as a cryoprotective agent in FBS alone. Cells in freezing medium are transferred into 
cryovials with each vial containing 10
6
 cells/ml, equivalent to the seeding density of 
25cm
2
 flasks. Cryovials are frozen initially at -80
o
C for 24 hours afterwards, in liquid 
nitrogen tank for months and years. 
 When cryopreserved cells are needed, they are thawed rapidly and residual 
DMSO is washed off with complete growth medium prior to seeding. 
 
4.3 Cell death analysis 
 
Cells were seeded in 6-well culture plates at determined number for flow 
cytometry analysis. After cells are attached to surface; they were treated with 30μM 
cisplatin, 50nm docetaxel* and 50nm paclitaxel* for 48 hours. At 48 hours, cells were 
harvested through trypsinization and washed twice with cold 1X PBS. The cells were 
centrifuged at 300g for 5 min, then the supernatant was discarded and the pellet was 
resuspended in 100μl 1X Annexin-V binding buffer then cell suspension was incubated 
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with 2μl of FITC-conjugated Annexin V (Pharmingen) for 15 min at room temperature 
in the dark. Five hundred μl of 1X Annexin-V binding buffer was added to each sample 
tube, and the samples were analyzed by FACS (Becton Dickinson) using FACS BD 
software. 
 
* This final concentration of cisplatin is based upon reported clinically achievable 
plasma concentrations as well as our own best dose response used in experiments and in 
vitro study. 
4.4 Total protein isolation 
 
Treated and control MCF-7, MCF-7/R6 and MDA-MB-231 cells were 
harvested, washed in ice cold PBS and lysed on ice in 200 µl complete lysis buffer 
containing freshly added 1 mM PMSF, protease inhibitor cocktail (Roche, Mannheim, 
Germany) and phosphatase inhibitors (Roche, Mannheim, Germany). After lysis of the 
cells for 30 min on ice, cell debris was removed by cold centrifugation (4
o
C) for 10 min 
at 13200 rpm. Supernatant contain total protein extracts which are immediately frozen 
and stored at -80
 o
C. Protein concentrations were determined with Bradford Protein 
assay. 
 
4.5 Cytoplasmic and nuclear protein isolation 
 
After treatment of MCF-7 and MCF-7 R6 cells with cisplatin for defined time 
points, nuclear proteins isolated from 60mm dish as follows; medium above the cells is 
sucked out, then cells are washed with ice-cold 1X PBS, after that scrapped within 1ml 
1X PBS and harvested by cold (4
o
C) centrifugation at 13200 rpm for 30 sec. Pellets are 
resuspended in 120μl of T1 buffer [10 mM HEPES/KOH, (pH 7.9), 10 mM KCl, 2mM 
MgCl2, 0.1 mM EDTA, 1% NP-40 with freshly added of 1 mM dithiothreitol (DTT) 0,5 
mM of PMSF, 1X proteases and phosphatase inhibitors]. Resuspended cells are chilled 
on ice for at least 20 min, then briefly vortexed and followed by cold centrifugation at 
13200 rpm for 1 min. supernatants contain cytoplasmic protein fraction. After 
supernatants are transferred to a new appendorf tube and stored in -80
 o
C, protocol is 
carried on with the remaining pellets for nuclear lysis process. Pellets are resuspended 
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in 20 all of T2 buffer [20 mM HEPES/KOH (pH 7.9), 1.5 mM MgCl2, 0,2 mM EDTA, 
650 mM Nail, glycerol (25%,v/v) with freshly added 1 mM of DTT, 0,5 mM of PMSF, 
1X protease and phosphatase inhibitors] and chilled on ice for  at least 20 min. 
Subsequently, cold centrifugation at 13200 rpm for 20 min is done to resuspends and 
resulting supernatant contain nuclear protein extract and immediately stored in -80
 o
C. 
 
4.6 Protein Content Assay 
 
Concentration of cytoplasmic and nuclear protein fraction is determined by 
Bradford assay which relies on the binding of the dye Coomassie Brilliant Blue G-250 
to protein, especially alkalic and aromatic amino acids found in protein. 
 
For measurement we diluted 1µl of protein sample with 4 µl distilled water in 95 
µl of 1X Bradford reagent.  In order to obtain a standard curve*, serial dilutions in 96-
well plate are done. BSA with standard concentration; 5, 2.5, 1.25, 0.625, 0.313, 
0.1570.078 μg of is used. By dividing the obtained optical density at 595 nm (OD595) 
to the slope of the calibration curve, the protein concentration is calculated in μg/μl. 
Calibration curve is used as long as R
2
 is smaller than 1.0 and larger than 0.9. 
 
*Standard curve is calculated for each experiment separately. 
 
4.7 SDS- polyacrylamide gel electrophoresis of proteins (SDS-PAGE) 
 
SDS-PAGE is the most widely used technique for analyzing mixtures of proteins. 
By this method proteins are separated on the basis of their molecular weight. They react 
with the anionic detergent sodium dodecylsulfate (SDS), present in the polyacrylamide 
gel and the loading buffer which gives negative charges to the protein complexes. SDS 
binds to the hydrophobic side chains of proteins and breaks non-covalent interactions. 
Before loading the sample onto the gel, it is mixed with loading-dye (2X), which 
contains β-mercapto-ethanol. The gel consists of polyacrylamide chains crosslinked 
with bisacrylamide. The polymerization of acrylamide and bisacrylamide is initiated by 
ammoniumpersulfate (APS) and catalyzed by N,N,N,N'-tetramethylenediamine 
(TEMED).  
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The gel consists of two parts, a stacking gel on top of a separation gel, which has 
a different pH and percentage of acrylamide. At the transition of the stacking to the 
separation gel, proteins are stacked to a narrow band caused by the difference in pH of 
the gels. Depending on the molecular weights of the proteins to be separated, different 
percentages of separating gels are used. Bio-Rad mini protean gel systems were used as 
protein gel electrophoresis.  
9, 12, 15% SDS-PAGE was used throughout the experiments; variation emanating 
from resolution of the vicinity of protein bands. 12% Separating gel is prepared by 
mixing; 3.4ml distilled water, 2.5ml pH 8.8 1.5M Tris-HCl, 50µl 20% (w/v) SDS, 4ml 
30% Acrylamide/ 0.8 bis-Acrylamide solution, 50 µl 10% APS and 5 µl TEMED in the 
given order (for 2 SDS-PAGE gels in 1mm glasses). Then gels were overlaid with 
distilled water to initiate air blockage and polymerization. Once the gel was 
polymerized, distilled water was removed and stacking gel was poured by mixing 
3.075ml distilled water, 1.25ml 0.5M Tris-HCl, 25µl 20% (w/v) SDS, 670 µl 30% 
Acrylamide/ 0.8 bis-Acrylamide solution, 25 µl 10% APS and 5µl TEMED in the given 
order (for 2 SDS-PAGE gels in 1mm glasses). Finally well combs were placed and 
waited for the formation of wells. Fully polymerized gels were put into gel tanks 
containing 1X running buffer. On the other hand, protein samples as being at equal 
concentration (20-30µg) was prepared with 2X loading dye. To break the disulfide 
bridges present in the protein, the mix is boiled at 95˚C for 3 min and then samples are 
shortly centrifuged. Together with the protein samples, a protein marker are loaded 
(Fermentas, Germany). This is a mixture of standard proteins with known molecular 
weights, which are coupled to a dye. In this way the standard proteins are visible on the 
gel and molecular weights of proteins in the loaded samples can be derived. SDS-PAGE 
was run for about 2 hours at room temperature with a constant voltage of 100V. 
 
4.8 Immunoblotting analysis 
 
Total protein lysates were separated on a 12% SDS–PAGE typically was removed 
from the tank for being transferred onto PVDF membranes.  
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4.8.1 Blotting 
PVDF transfer membrane (Roche) is firstly soaked in Methanol for 30 sec to be 
activated. Whatman papers, sponge which are soaked into freshly prepared 1X Transfer 
buffer are placed above and below of SDS gel and  nitrocellulose membrane within 
cassettes. The cassettes were placed into the transfer tank which is filled to the top with 
1X TB. Transfer tank was also containing an ice-block to prevent heating and to ensure 
a constant voltage of 100V during 1.5 hours at 4 
0
C. 
 
4.8.2 Blocking 
To remove residual methanol, membrane is washed with distilled water or 1X 
PBS-T briefly. Blocking solution (5% (v/v) dried milk powder in PBS-T) is used to 
block membrane; 1 hour incubation at room temperature was done. 
 
4.8.3 Antibody 
After a quick washing of the blocked membrane with PBS-T, membrane is 
incubated with primary antibodies in 1:2000 (v/v) dilution for 2 hour at room 
temperature or overnight at cold room (4
o
C). Primary antibodies are listed in Appendix 
B. 
 Then membranes are washed with 1X PBS-T for 3 times for 15min. Afterwards, 
Membranes incubated with secondary antibody, HRP coupled anti-rabbit or anti-mouse 
IgG in 1:5000 (v/v) dilution for 2 hour at room temperature. Then second washings are 
done; membranes are washed with 1X PBS-T for 3 times for 15 min. Then substrate for 
HRP (ECL Advance Chemiluminescence) incubation is added at 1:1 and placed in 
cassette. In the dark room, membranes are exposed to Hyperfilm-ECL and developed 
manually to visualize proteins band clearly. 
ECL Advance Chemiluminescence Substrate is a highly sensitive nonradioactive, 
enhanced luminol-based chemiluminescent substrate for the detection of horseradish 
peroxidase (HRP) on immunoblots. ECL Advance Chemiluminescence Substrate 
enables the detection of picogram amounts of antigen and allows for easy detection of 
37 
 
HRP using photographic or other imaging methods. Blots can be repeatedly exposed to 
X-ray film to obtain optimal results or stripped of the immunodetection reagents and re-
probed. 
 
4.9 Electrophoretic mobility Shift Assay (EMSA) 
 
Electrophoretic mobility Shift Assay is based on reduced electrophoretic 
mobility of protein interacted with DNA (radioactively labeled probe) through a-non 
denaturing poly acrylamide gel compared to unbound labeled DNA probes. 
 
4.9.1 Labeling of Probes 
The oligonucleotides with 5’-OH (*) blunt ends (NF-κB and Foxo3a) were 
labeled with γ-32P-dATP (3000 Ci/mmol) using T4 polynucleotide kinase (Promega). 
The reaction mix is assembled in 50 µl in total which contains 10.25 µl ddH2O, 15 µl 
NF-κB oligonucleotide (1.75 pmol/µl, final: 26.25 pmol), 5µl T4 kinase buffer (10X, 
final: 1X), 15.75 µl γ-32P-dATP (3000 Ci/mmol, final: 52.5 pmol, 170 µCi) and T4 
kinase (5U/µl final: 20 Units). The mix is incubated in a 37oC waterbath for 10 min. 
 Labeled oligonucleotide was purified on a Sephadex G-25 column (Roche). 
Column was washed completely off its buffer first by gravitation, then by centrifugation 
twice at 3500 rpm for 2 min. then 50 µl of reaction mix is applied to the center of the 
column in an upright position. After the column is placed in a new collection tube, the 
collection is centrifuged at 2300 rpm for 4 min. Eluate in the collection tube contains γ-
32
P-labeled NF-κB and Foxo3a consensus oligonucleotides. 
 
4.9.2 Binding Reaction 
The binding reaction mix is assembled 20 µl in total and probe is added last. After 
addition of probe, binding reaction is allowed to proceed for 30 min at room 
temperature. Total volume is completed to 20 µl with distilled water. For supershift 
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experiment; 1.5 µl anti-p50 and anti-p65 are added to the binding reaction mix after 10 
min before addition of 
32
P-labelled oligonucleotide probe. 
 
4.9.3 Vertical gel electrophoresis 
6% non-denaturing polyacrylamide gel containing; 24 ml dH2O, 10ml of 1X 
TBE, 6 ml  30% Acrylamide/ 0.8 bis-Acrylamide solution, 280 µl 10% APS, and 36 µl 
TEMED. The comb inserted carefully and gel is left to polymerize for 1 h. then gel is 
pre-run in cold 1X TBE at 180 V at least for 30 min. In the meantime; 3 µl EMSA 
loading dye is added to the binding reaction mixes which has just completed 30 min 
period of incubations at room temperature at dark. Then mixtures of protein and DNA 
are loaded into gel and run at 300 V for 3hrs until bromophenol blue migrates ¾ 
distance of the gel.  
     Next, the gel was dried at 80
o
C for 45 min - 1 h. Dried gel is put into a film 
cassette and kept at -80
o
C and then autoradiographed on Kodak X-ray film. 
The consensus sequences of the oligonucleotides used in this work were as 
following; For NF-κB; 
5’- AGT TGA GGG GAC TTT CCC AGG C-3’ 
 
For Foxo3a; 
5’- ATTGCTAGCAAGCAAAACAAACCGCTAGCTTA-3’ 
 
4.10 RNA isolation 
 
MCF-7 and MCF-7/R6 cells lysed in TRIzol (Invitrogen, Germany) and total 
RNA was isolated according to the manufacturer's protocol. 
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4.11 RNA integration test 
 
10X MOPS (final: 1X) buffer and 37% formaldehyde (12.3M, final: 18% of 
total volume) was used for preparation of 1% agarose gels. 1X MOPS running buffer to 
cover the gel gels was used. In the meantime, 2 µg of RNA in 2X RNA loading dye 
containing intercalating 0.025% ethidium bromide (Fermentas) was prepared. 2X RNA 
loading dye contains the tracking dyes bromophenol blue and xylene cyanol FF. After 
removing the combs, and loading RNAs to the gel, gel was run at 100 V for 45 minutes. 
RNA was visualized under UV rays by using UVITEC (UVIdoc Gel Documentation 
System, UK) machine. 
Quantity assessment of RNA was done via spectrophotometer at an optical density 
at 260 nm (OD260).  Just prior to shipping to Cleveland Clinic (Ohio, USA), 
concentration was calculated using the OD260/280 ratio. 
 
4.12 Statistical analysis of cell death graphics 
 
All samples were evaluated statistically using an excel function toolbar 
(TTEST). Relative cell death of treated cells compared to control was shown as mean ± 
standard deviation, and the student’s t-test was applied to understand if values are 
significant or not. P≤0.05 (*) and P≤0.01 (**) were considered as significant. 
 
4.13 Microarray 
 
cDNA and biotin-labeled cRNA synthesis was generated from 250 ng total RNA 
using the Illumina
® TotalPrep™ RNA Amplification Kit (Applied Biosystems, 
Darmstadt, Germany). cRNA was quantified using a nanodrop spectrophotometer and 
the cRNA quality (size distribution) was further analyzed on a 1% agarose gel. cRNA 
(1.5 μg) was hybridized to Human WG-6 Expression BeadChips V1 and V2 Illumina, 
(San Diego, CA) and scanned on Illumina BeadArray reader. The data was 
subsequently imported into Illumina's BeadStudio software and probe and gene level 
output files were generated as an excel format. 
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4.13.1 Data and statistical Analysis of microarray 
 
Microarray data were analyzed by using MATLAB 2009b. The method used is 
explained in detail in the result section. 
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5. RESULTS 
 
 
 
 
5.1 Establishment of cisplatin resistant MCF-7 cell line 
 
5.1.1 The unique method for generation of cisplatin resistant breast cancer cell line 
In order to obtain cisplatin resistant cell line, both MCF-7 and MDA-MB-231 
cells are first treated with a low dosage of the drug medium which corresponds to 1µM 
cisplatin for 4 days, and then after sucking the low dosage drug medium from the cells, 
cells are treated with a high dosage of the drug medium which corresponds to 30 µM 
cisplatin for 4 hours [represented in Figure 5.1]. Cells are washed with a drug free 
medium in between the low to high dosage treatment transition. This treatment is 
repeated periodically until cell death declines to low rate. Using this pre-treatment 
method we aimed by that: only drug resistance genes will be stimulated rather than anti-
apoptotic or survival genes. In this way we could see which genes were responsible for 
resistance status. Also by applying this treatment, we aimed for less cell death because 
resistant genes were already targeted to express at high rate by applying a low dosage of 
the drug during the 4 days period. Therefore, cisplatin treatment which is 30 times more 
compared to pre-treatment (1µM-30µM) for short period of time will not affect cells 
and they will survive at a high rate. 
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Figure 5. 1: Diagram representing our unique method for generating resistant cells. 
 
 
5.1.2 Testing cells for cell death with flow cytometry 
After each period of treatment, cells were seeded to 6 well plates for performing 
cell death analysis. In order to make cells adhere, one day of waiting time was given to 
the cells. After cells were treated with 30µM cisplatin for 48 hours, a flow cytometry 
experiment was conducted. A graph of Flow cytometry data after applying the t-test is 
shown in Figure 5.2 and 5.3. 
In addition, the total proteins of the newly established cell lines (R1, R2…) were 
isolated and for back up purpose, each cycle of treated cell was frozen and stored at -
80
o
C. At the end of each treatment cycle, we expected to see some cell clones survive. 
After 6 months of continuous treatment for MCF-7 cells and after one and half month 
for MDA-MB-231, cells became relatively more resistant to the cisplatin treatment. In 
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the flow cytometry experiment, Annexin V positivity level, which represents the 
apoptosis rate in cell clones, was checked and this rate declined after periodic drug 
treatment [Figure 2, 3]. Cells that retained drug and showed low rate of death were 
called “MCF-7 R6” for MCF-7 cells and “MDA-MB-231 R2” for MDA-MB-231 cells. 
 
5.1.3 Examination of MCF-7 cell line derivatives 
In Figure 5.2B, the level of apoptosis rate change by the time is depicted.  
Typically, control MCF-7 cells undergo apoptosis between 10-15% without drug 
treatment for 48 hours. On the other hand, MCF-7 cells treated with 30µM cisplatin for 
48 hours undergo apoptosis between 30-35 %. The average apoptosis percent values at 
the end of each cycle of cisplatin treatment are shown in Table 5.1. As the cell line 
progresses, the apoptosis rate of control cells become less. For the cisplatin treated cells, 
there is no such direct relationship. They behave individually. The first line of the clone 
cell, called “R1”, act like a pair of non-resistant MCF-7 cells. But this graph only shows 
numerical data, in fact R1 cells experienced crucial changes biologically that affect the 
metabolism and also attachment of the cell. After the cycle of drug treatment, we give 
cells time to recover. Recover, in this case means that cells that have initiated death 
signaling and start to secrete death molecules should be washed away from the flask. 
Cells that adhere to the bottom of the flask should cover approximately up to 80% of 
total area. In the recovery phase, we changed the medium regularly with 10% FBS 
DMEM until only adherent cells were left.  This recovery phase is different for each 
cycle of cell. For “R1” clone cells this recovery time period was approximately 1 
month. In normal MCF-7 cells, passaging of cell should be done twice a week so this 
significant difference shows that substantial changes start to occur in parental MCF-7 
cell lines. Table 5.1 shows the recovery time for each cycle of treatment. 
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 MCF-7/R (% Apoptosis) 
 Control Cisplatin 
R1 13,4 33,5 
R2 10,2 12,9 
R3 10,1 23,3 
R4 7,97 10,63 
R5 6,43 15,6 
R6 4,57 13,43 
 
 
Figure 5. 2: A: Graph of all cell line is combined. Diminishing apoptosis rate of the 
control cell (R1-R6) is shown at the right and fluctuating values of treated cells shown 
at the left of the graph. B: Mean values of triplicate data showing apoptosis rate in 
percent. 
 
A 
B 
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In the “R2” and “R4” cell lines, there is very small variance between the control and 
drug treatment. This 2-3% difference is not normal for a resistance experiment, 
according to drug resistance cell line experiments reported previously. The apoptosis 
rate should be grater after drug treatment otherwise data is considered as not significant. 
As a result we did not trust these 2 cell lines (R2 and R4) as being resistance and we 
maintained the treatments. In “R5”, the expected value was achieved but our control 
cell, non resistant MCF-7 cells, did not work well due to over-confluency and we did 
not consider “R5” cell line was reliable either. In “R1” and “R3”, there is significant 
difference between the two cases and clearly they are not resistant. Last, “R6” provides 
a match so we used this cell line as a keystone for our further studies. Its control, MCF-
7 also worked pretty well in the same set-up of experiment.  
 
Table 5. 1: Recovery time required for each cycle of treatment. The right column 
shows the days required for MDA-MB-231 cell line derivatives to recover. The left 
column shows days required for MCF-7 cell line derivatives to recover. 
 MCF-7   MDA-MB-231  
R1 27days  R1 43 days 
R2 11 days  R2 17 days 
R3 10days  R3 14 days 
R4 21 days  R4 6 days 
R5 6 days    
R6 10 days    
 
 
The fluctuation of the apoptosis rate shows that the resistance status is not stable for 
each cell line. This was confirmed by prolonging treatments to “R11” and by 
conducting flow cytometry. Once the cells became cisplatin resistant, protein isolation 
for EMSA and western blotting and also cryopreservation were done. Freezing and 
thawing sometimes kills resistant cells, as stated in the literature, however resistant cell 
death did not occur in this study. After thawing the cells for different drug trials, the 
cells showed nearly the same reaction to the cisplatin treatment. Thawing of the cells 
was done after 6 months; they were not affected by the temperature. 
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5.1.4 The MCF-7 “R6” cell line: 
The apoptosis rate caused by cisplatin decreased from 32.7 % to 13.4 % [Figure 
5.3A]. In the histogram graphs, shift of the peak entering to the gate (P2) is seen 
obviously in Figure 5.3B.  
 
Figure 5. 3: A: Detailed graph of MCF-7 R6 data. B: Flow cytometry graphs of 
MCF-7 R6. The right side is shows a dot plot, in which each dot represents cells. P1 
shows selected parental cell population. The left side graph is a histogram. It shows how 
intense P1 parental cells are stained and how much light they emit. 
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The peak’s shift to the right means more cell population undergo cell death. The top 
graph shows the percentage of “R6” cells that die without cisplatin treatment and 
bottom graph shows the percentage of cells that undergo cell death after treating “R6” 
cells with 30µM cisplatin for 48 hours. 
 
Table 5. 2: Triplicate of data obtained in cisplatin treatment of MCF-7 “R6” cell 
line. 
    1 2 3 total SD 
Normal  MCF-7 
  
Control 10,3 10,8 10 10,37 0,40 
Cisplatin 32,9 32,6 32,7 32,73 0,15 
MCF-7 “R6” 
  
Control 4,5 4,5 4,7 4,57 0,12 
Cisplatin 13,4 13 13,9 13,43 0,45 
 
 
A decline in the percent of control cells is also seen. Normal MCF-7 cells die at 
13.43% but MCF-7 “R6” cells die at 4.57%. A nearly 20% increase in cell survival is 
seen. Control MCF-7 “R6” cells start to die at a low percent. The figure 5.2 shows the 
decline in all cell lines that continuously treated with cisplatin. Cisplatin makes cells 
secrete some materials that activate survival mechanism so cells overcome the death 
effect of cisplatin and begin to survive. This data shows that at the constitutional level 
of MCF-7 “R6” one or more survival pathway becomes active. Further experiments 
seek to identify the survival pathway. 
This 20% decline shows that the cisplatin resistant cell population in the total 
population is much higher than the non-resistant MCF-7 population. Due to the resistant 
colony that come uppermost, cisplatin seems to kill fewer cells than normally does.  At 
protein level, by looking at total proteins, we can see some fundamental differences. 
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5.1.5 Cell morphology 
 
After a long period of treatments, cells begin to reshape their cytoskeleton and 
change their morphology. They began to resemble the other strain of breast cancer cell 
line, MDA-MB-231. 
 
Figure 5. 4: Morphology of resistant cell. The upper left belongs to MCF-7 cells, 
the upper right belongs to MCF-7 “R6” cells and the bottom belongs to MDA-MB-231 
[normal cell pictures are retrieved from atcc.org]. 
 
Normal MCF-7 cells have a circular shape and are capable of forming domes. They 
grow on top of themselves rather than expanding colonies to the bottom of the flask. As 
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the cell line progresses and cells retain more cisplatin into them, their shape begins to 
change and shift towards MDA-MB-231 cells. Just like MDA-MB-231 cells, resistant 
cells also begin to have extension rather than having a circular shape. They grow by 
expanding individually; few numbers of colonies are seen. They are not thin and 
elongated as MDA-MB-231 but compared to normal MCF-7 they have propagations. 
Normally MDA-MB-231 cells die at a rate of 10-15% after treatment with cisplatin. 
The resistant MCF-7 cell line also have a death rate in between, so metabolically the 
similarity between these 2 cell lines can be understood by looking at the morphology 
[Figure 5.4]. 
Also they start to behave in an extraordinary way. Normally, trypsinization of cell 
for passaging takes 5 minutes or less but in our case it began to take up to 10 minutes. 
So as the cell line progresses, trypsinization of MCF-7 cells started to be challenging. 
They tightly bind themselves to the bottom of the flask. Also the size of the cells began 
to be decrease. 
 
5.1.6 Different drug trials on MCF-7 “R6” cells 
After obtaining successful results for the MCF-7 resistant cell line, we wanted to 
question if this cell line is also resistant to other anticancer agents; Docetaxel and 
Paclitaxel. These 2 agents belong to the same class of anticancer agents, taxol. 
Docetaxel and Paclitaxel inhibits microtubule dissociation and are used as a microtubule 
stabilizer. 
After thawing the MCF-7 “R6” cell line, we waited about 15 days for the cells to 
reach high cell number. After passaging them, we seeded cells into 6 well plate at 
300.000 cells/well. After waiting one day to make them attach to the surface, we treated 
them with 30µM cisplatin, 50nM Docetaxel and 50nM Paclitaxel for 48 hours. The gate 
of flow cytometry was adjusted according to the default cisplatin percent which is 
between 30-35%. All calculations were done based on control MCF-7 cells.   
In general, after different drug treatments, resistant MCF-7 cell death was lower 
than normal MCF-7 cells in each treatment case [Figure 5.5]. Also MCF-7 “R6” cells 
did not seem to be affected by different drug treatments. At most 4% of MCF-7 “R6” 
cells die by the treatments. But in normal MCF-7 cells, Paclitaxel and Docetaxel caused 
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cell death at a rate similar to cisplatin. In normal MCF-7 cells, drugs kill between 9.9 - 
18.1% of the cells whereas in MCF-7 “R6” cells this rate decreases to 2.2- 4.1%. 
 
Figure 5. 5: A: Graph of different drug treatment results. B: Data showing average 
data of triplicates obtained from flow cytometry. Treatments were done for 48 hours. 
 
Therefore this result explains how cisplatin resistant cells over-activated the survival 
mechanism which prevented them from undergoing apoptosis. In this way, cisplatin 
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resistant cells become death resistant and start to act like aggressive tumors. 
Hyperplasia is also seen.  Corresponding doses of Docetaxel (50nM) and Paclitaxel 
(50nM) which were tested before in our lab were used.  
 
5.1.7 Serum treatment of normal MCF-7 cells 
A further study was undertaken on MCF-7 “R6” cells to understand if extracellular 
ligand secreted from resistant cell made MCF-7 cells survive against cisplatin. To test 
this hypothesis, the medium above the resistant cells were taken and kept at -80
o
C.  
The medium was taken after 4 days because we aimed to have abundant amount of 
ligand and protein which were responsible for cell survival and exist in the medium. In 
this way we can see a dramatic effect caused by abundant ligand. After thawing the 
serum, we divided it into two.  Half of it was filtered with a 0.22µM filter and half of it 
was not filtered. Then these serums were applied for 2 days to the normal MCF-7 cells 
to examine apoptosis rate of cisplatin and other drugs. 
As seen in Figure 5.6A, the filtered serum treatment of normal MCF-7 cells enabled 
them to survive at a high rate similar to MCF-7/R6 cells. The death rate caused by 
cisplatin treatment of MCF-7 cells declined from 33.2% to 12.8%. Also the death rate of 
control cell also declined from 20% to 17%. These results are very similar to resistant 
cell line results. This shows that some elements present in the serum of MCF-7 “R6” 
cell line have a vital role in the survival mechanism. 
Non filtered serum did not work well on MCF-7 as seen in Figure 5.6B because the 
death rate of cisplatin increased from 32.8% to 41.2%. Also other drugs were tried but 
compared to their control, the death rate always increased except for the Docetaxel 
treatment. Non filtered serum seems not to have affected the survival mechanism. A 
possible reason can be that the apoptotic ligand may have a size bigger than the filter so 
high amount of the ligand is left in the filter and in this way could not activate the cell 
death mechanism. 
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Figure 5. 6: Treatment of normal MCF-7 A: with filtered MCF-7 “R6” cell serum 
B: with non-filtered serum. C: Shows average data of triplicates obtained from MCF-7 
“R6” serum treatments. 
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5.2 Microarray Results 
 
5.2.1 RNA isolation: 
After generating a resistant cell line, in order to have a general view about gene 
expression and compare it with normal MCF-7; the RNA of both were isolated for 
microarray experiment. RNA isolation was conducted with TRIZOL
®
.  
 
5.2.2 RNA quality: 
Prior to shipping an RNA integrity test must be performed in order to be sure if the 
RNAs of the samples are intact or not. RNA quality was checked with Denaturing 1% 
agarose gel, which was run in 1X MOPS buffer. 2 bands were aimed to seen. One band 
stands for large ribosomal RNA subunit which is 28S; the other band stands for small 
ribosomal RNA subunit which is 18S [Figure 5.7]. In this gel figure, we see a sharp 
band which means there is no RNA degradation in the 1 month period. If there was a 
smear, this would mean RNA had started to be ubiquinitated and some of it would be 
degraded. The samples were integrated. Also from this figure, we can estimate that the 
concentration of N1 and N2 RNA is higher than R1, R2 and R3 RNA. Also we should 
see 28S band intensity must be two times more concentrated than 18S band, which was 
seen. 
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Figure 5. 7: RNA quality assay.  N stands for Normal MCF-7 RNA and R stands 
for MCF-7 “R6” cell line RNA. We had triplicate RNA of each group. The ladder was 
expired so it was degraded and seen as a smear band at L lane. 
 
 
5.2.3 RNA Concentration 
Desired RNA concentration for microarray experiment was 200 ng/µl. We got RNA 
concentrated than that. After RNA dilution to equal concentration that is 200 ng/µl and 
volume is 20 µl; RNAs were shipped to Cleveland genomics center, OHIO, USA. 
 
Table 5. 3: RNA concentration. Samples are measured in 3 biological replicates and 
in ng/µl. 
Sample(ng/µl) 1 2 3 
Normal MCF 424.87 541.91 542.0 
MCF-7 "R6" 142.08 49.52 207.49 
 
 
5.2.4 Microarray chip 
Illumina Human WG-6 BeadChip array was used for gene expression experiments. 
It contains 48,000 bead types and takes 6 samples simultaneously. The array reader 
identifies each DNA oligomers using an autonomic registration algorithm [100] and a 
molecular address [101]. DNA sequences attached to the bead are 75 base pairs in 
length: 50 base pairs for target hybridization and 25 base pairs for decoding purposes. 
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From the image of the array using image processing techniques, numerical values are 
obtained and written in an excel file by BeadArray 
TM 
software. We downloaded this 
excel table from a universal domain. These data were not normalized but background 
subtraction was already made by US collaborators. 
 
5.2.5 Data analysis 
After downloading the excel file, genes that had negative values were eliminated 
because negative values mean that the background emits more light than the sample, 
that would probably sourced by either experimental error or maybe gene probe did not 
bind properly to the target.  
Therefore we eliminated this gene manually. By manually we mean that we 
calculated the mean values of triplicates and then sorted them using an excel sorting 
filter and deleting rows with a negative value. 
5.2.6 MATLAB 
MATLAB 2009b was used for statistical analysis. I wrote a code that only picks 
the significant genes from the gene pile and writes them into a separate text file. Code 
strings are shown in Figure 5.8. 
All data was normalized to the GAPDH gene which is generally used in RT PCR 
normalization. The expression level of this gene is nearly same for all cells. We did this 
for each value of normal MCF-7 and MCF-7 “R6”separately.  
 Then we executed the code in Figure 5.8. In the first step, the code finds NaN 
values in the excel spreadsheet; If there are any NaN values, it changes NaN into a 
mean value which is specifically calculated for the row. We need remove NaN values 
because they are non-numerical values and prevent calculation and analysis. 
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fid = fopen('normalized data.txt', 'r+'); 
s = size(data,1);                                        
ALLDATA=data(:,1:6);                                   
NAN=findstr('NaN', s);                                    
D = zeros(s, 6); 
for i = 1:s                                               
    D(i,:) = ALLDATA(i,:); 
end 
C = D(1:s, 1:3); R = D(1:s, 4:6); 
for i=1:s 
    MeanC(i,1)=mean(C(i,1:3)); 
    SigmaC(i,1)=std(C(i,1:3)); 
    MeanR(i,1)=mean(R(i,1:3)); 
    SigmaR(i,1)=std(R(i,1:3)); 
    for j=1:3 
        OutlierC(i,j)= abs(C(i,j)-MeanC(i,1)) > 3*SigmaC(i,1); 
        OutlierR(i,j)= abs(R(i,j)-MeanR(i,1)) > 3*SigmaR(i,1); 
    end 
end 
fid = fopen('significants.txt', 'wt'); 
count_t = 0; 
count_r = 0; 
for i=1:s 
    if(jbtest(C(i,1:3))==0) 
        test_result(i,1) = ttest2(C(i,:), R(i,:)); 
        count_t = count_t + 1; 
    else  
        [p,h] = ranksum(C(i,:),R(i,:));                             
test_result(i,1) = h;    
        count_r = count_r + 1; 
    end 
    if(test_result(i,1) == 1) 
         
fprintf(fid,'%s\t%s\t%8.3f\t%8.3f\t%8.3f\t%8.3f\t%8.3f\t%8.3f\t'
,...                        
           
char(textdata(i+1,1)),char(textdata(i+1,2)),D(i,1),D(i,2),D(i,3)
,D(i,4),D(i,5),D(i,6)); 
    end 
    fprintf(fid, '\n');      
end 
 
Figure 5. 8: the code string. 
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In the following step, the code eliminates outliers if the absolute of the average 
minus gene value is more than three sigma, it is considered an outlier and program does 
not write this gene into matrix so this gene is eliminated. The program scans and 
calculates these values for each row. 
In the next step, the program checks if the gene values are normally distributed. For 
checking distribution, we used a jbtest command. This commands usage is optional. 
There are many codes that can be used in analysis. If the data is distributed normally, a 
jbtest gives a value 0 and then ttest2 command is executed automatically. The ttest2 
performs paired t-test. This code was picked because we have 2 groups which contain 
the same number of repetition and the same type of cell. If the gene passes both jb-test 
and t-test, then it is written into the significants.txt file. If data is not distributed 
normally, jbtest gives a value 1, then it performs rank sum test.  Default p-value of t-test 
is p ≤ 0.05. So genes in the Significant.txt file were trustable at least 95%. The program 
writes all information about the genes and values of each row together to a txt file. 
In total, there were 48803 genes, after executing the code, 5639 genes were left. 
11.6% of the data remained at p ≤ 0.05 and 88.4% was eliminated. We also performed 
benforoni correction (BC) and after BC, only 10 genes were left which means only 
0.021% of the data remained. 
Significant.txt file was used as a fundamental datafile for this study. The folds of 
Resistance/Normal (R/C) were also calculated from mean values. According to fold 
results western blot experiments were performed. 
 
5.2.7 Microarray results as tables 
If genes are classified according to functions generally known, most of the gene 
expression can be said to be drastically changed in MCF-7 “R6” cell RNA compared to 
normal MCF-7 cell RNA. 
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Table 5. 4: classification of genes according to functions 
 
Entity Number 
Cell Death 28 
Growth factor 16 
CD 14 
Cell cycle 6 
DNA repair 7 
Drug Resistance marker 7 
NF-KB 12 
MAPK 14 
 
 
As a general aspect, gene expression of growth factors increased up to 4 fold in 
MCF-7 “R6” cells. The apoptotic protein level declined but some Bcl-2 member levels 
increased in resistant cells. The expression of known drug resistance markers started to 
be built up at a constutional level in cisplatin resistant cell. The gene expression level of 
DNA repair enzyme increased in MCF-7 “R6” cells. Cell cycle protein level is elevated 
in MCF-7 “R6” cells compared to normal MCF-7 cells. Also levels of WNT, NF-κB 
and MAPK pathway entities increased in MCF-7 “R6” cells. 
 
5.2.8 After Benforoni correction 
The Benforoni correction is calculated from the following formula; 
Benforoni Correction = 
genesofnumber
valuep


 
 It only aims to select genes that have p-value less than 
48803
05.0
  which is equal to 
0.0000102. The genes that are listed below have that p-value so their variance is very 
low and similar to each other. 
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Table 5. 5: list of the most significant genes after Benforoni correction 
 
 
 
Figure 5. 9: classification of 10 genes by using Euclid distance (Cluster 3). Black 
color refers to increased gene expression and green means decreased gene expression 
level. 
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PINK1 gene expresses serine threonine kinase and localizes to mitochondria [102-
104].  In cell culture studies the overexpression of PINK1 protects cell against apoptotic 
stimuli and stress whereas siRNA mediated depletion sensitizes cell to apoptotic threats 
[105]. In this study, PINK1 level is decreased 0.7 fold in resistant cells compared to 
normal cells and this contradicts with previous studies. 
TPCN2 localizes in ER and lysosome. It is a two pore cation channel which forms 
lysosomal NAADP-sensitive Ca
+2
 releases. In resistant cells, level of this gene raised to 
1.4 fold [108]. 
P2RY2 product belongs to the family of G-protein coupled receptors. This family 
has several receptor subtypes with different pharmacological selectivity, which intersect 
in some cases, for various adenosine and uridine nucleotides. This receptor is sensitive 
to both adenosine and uridine nucleotides [137, 138]. This gene is expressed 2.25 times 
more in cisplatin resistant cells breast cancer cells. 
The CCNG1 gene level in resistant cells is 0.44 less than normal MCF-7 cells. 
Transcriptional activation of this gene is induced by p53 gene and p53 gene level is 
nearly half of normal MCF-7 cells therefore p53and this gene seems to be acting 
simultaneously in drug resistant cases [139]. 
The GSK3B gene is part of energy metabolism and Wnt pathway which is involved 
in cell differentiation, cell movement, polarity and proliferation [reviewed in ref 140]. 
GSK3B inhibits β-catenin to enter to cytoplasm and activates TCF/LEF transcription 
factors. One of the targets of TCF/LEF transcription factors are c-jun, c-fos and cyclin 
family of proteins [141]. Here, the level increased in resistant cells at 1.42 fold. But the 
Wnt pathway is overactivated in resistance cells up to 3 fold therefore this increase of 
GSK3B is related to non-canonical Wnt pathway probably. 
FLAD1 catalyzes the adenylation of flavin mononucleotide (FMN) to form flavin 
adenine dinucleotide (FAD) coenzyme [retrieved from genecards.org].  the level of this 
gene ascended 1.67 fold in resistant cells. 
KEAP1 regulates cytoprotective gene expression under stress conditions and is 
suppressed under unstressed conditions by inhibiting Nrf2. The level rise of KEAP1 at 
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1.4 fold explains how cells start to be insensitive to oxidative damage of cisplatin [109, 
110]. 
ACTA2 is involved in cell motility, structure and integrity by polymerizing and 
depolymerizing of fibrils. Also it forms polar tracks within the cell and in this way helps 
motor proteins and vesicle transport system. Actin is linked to E-cadherin and beta-
catenin at adherens junctions. This gives mechanical support and durability to cells. It 
may be the cause of cells to adhere surface much more than initial state. It is 10.3 times 
more in MCF-7 “R6” cell line. Cytoskeletal changes occurred to MCF-7 “R6” cell line 
in transition from cisplatin sensitive to resistance phase [retrieved from TOCRIS]. 
The functions of RWDD2A and YRDC genes are not known.  
5.3 Selected genes 
5.3.1 Drug resistance markers 
 
There are already characterized drug resistant genes and they are characterized in 
other cell lines. In this section of the study, we want to examine if the drug resistant 
marker genes already known also play a role in breast cancer cisplatin resistant cells.  
 
Table 5. 6: Drug resistance genes. 
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Table 5.6 shows that known genes are also involved in drug resistance but gene 
variants differ in some way. The GST protein has pi variant called GSTP1 gene which 
was expressed 2 times more in resistant cells than normal cells. Another type of GST, 
the MGST1 variant 1b, was nearly 2 times more expressed in MCF-7 “R6” cells. 
Metallothionein is also expressed more in oxidative stress formation and in resistant 
cells metallothionein 1F and 1H were expressed 1.3 times more. 
The solute carrier family 31 is for exports copper and drug outside of the cell and 
occured 1.32 times more in resistant cells. In this way it can pump the drug out of the 
cell. 
ATP binding cassettes are the largest and most ancient family of transporters. It 
utilizes energy to translocate several substances such as drug and the neutralized form 
of drug. Only ABCB6 and ABCB9 gene transcript variant 2 cassettes are expressed 
nearly 2 times more in MCF-7 “R6” cells. 
 
5.3.2 Genes related to Cell Death 
Apaf-1 has 2 transcript variants that do not differ in function. Apaf-1, BID, Caspase-
6, CFLAR, CRADD, TUSC1, TUSC4, XAF1 and FOXO-1, FOXO-4 level declined in 
resistant cell. Pro-apoptotic members are: Apaf-1, BID, FOXO-1, FOXO-4, Caspase-6, 
CFLAR (key molecule between cell death and cell survival), and CRADD (apoptotic 
adaptor). TUSC1 is a tumor suppressor gene; as its level decreases, tumors become 
aggressive [provided by RefSeq]. 
The level of BCL, DAP, DAPK and ATG family proteins raised at 1.09- 1.99 fold. 
Some autophagy related genes seem to be increased such as ATG16, ATG3 and 
ATG4C. 
Apaf-1 is a pro-apoptotic member of apoptosis proteins and XIAP is anti-apoptotic 
member. In the microarray data, the Apaf-1 expression level seems to be decreased to 
half in MCF-7 “R6” cells. At protein level, expression of Apaf-1 decreased to half 
therefore here gene expression level and protein level seems to be regulated in parallel.  
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Figure 5. 10: Immunoblotting of Apaf-1, XIAP, Aven and β-actin. 
 
Apaf-1 has 2 transcript and protein variants so these 2 bands that are 130 and 
140kDa are seen in Figure 5.10. In the R column which corresponds to resistant cell 
line, the very faint band of Apaf-1 is seen. Apaf-1 level is decreased at 0.5 fold in both 
total proteins and gene expression level of MCF-7 “R6”. 
As seen in the Figure 5.10, XIAP is upregulated at the protein level whereas XIAP 
associated factor 1 (XAF1) transcript variant 2 gene expression level was 
downregulated at the RNA level. It shows that, gene expression and protein expression 
levels do not always have to be parallel. 
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Aven is a caspase activation inhibitor and binds to pro-apoptotic proteins such as 
Apaf-1, Bcl-xL.  Aven level is upregulated in MCF-7 “R6” cell line. Therefore the 
resulting Apaf-1-Aven complex overcomes apoptosis.  
 
Table 5. 7: Cell death related genes. 
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5.3.3 Foxo family 
The gene expression level of Foxo-1 and Foxo-4 decreased 0.45 and 0.33 fold 
respectively in resistant cell. Foxo-1 and Foxo-4 are apoptotic proteins and their 
presence at a low-level is appropriate for cisplatin resistant cells [Figure 5.11].  
 
 
Figure 5. 11: A: Foxo family gene expression folds B: Graph of Foxo-1 and Foxo-4 
(Microarray data). 
 
The total protein level of Foxo-1, Foxo-3a and Foxo-4 was checked by 
immunoblotting. In the control cell, there is more Foxo-1, Foxo-3a and Foxo-4 than in 
MCF-7 “R6” cells. Phosphorylation of Foxo-1 at Ser 256 and at Thr-24 was checked as 
well. Foxo-1 is 78-82 kDa, Foxo-4 is 65 kDa and Foxo3 is 82 kDa. Phosphorylation of 
Foxo-1 from both residues was higher in the cisplatin-resistant MCF-7 cells than normal 
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MCF-7 cells. A very faint band can be seen in the total protein level of Foxo-1 in MCF-
7 “R6” and P-Foxo-1in Normal MCF-7 cells [Figure 5.12]. 
 
Figure 5. 12: Protein level of Foxo family proteins. A: Foxo-1, B: Foxo-3a, C: P-
Foxo-1 at Ser-256 D: Foxo-4 E: P-Foxo-1 atThr-24 F: β-actin 
 
EMSA for Foxo-3a is performed with normal MCF-7 cells and MCF-7 “R6” cells. 
In normal MCF-7 cells there is very low level of Foxo-3a activation in the nucleus. In 
the resistant cells, there is a high level of Foxo-3a transactivation [Figure 5.13]. Western 
blots showed very slight changes in the level of Foxo-3a but EMSA showed a drastic 
increase in the nucleus. This extreme difference may resulted from the resistance case. 
As the cell line progresses to being resistant, the total Foxo-3a protein level decreases to 
become very close to the basal level of the MDA-MB-231 cell line [Figure 5.14]. 
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Figure 5. 13: EMSA results for Foxo 3a. The first lane contains the free probe, the 
second lane contains the nuclear isolate of normal MCF-7 cells and the third lane 
contains the MCF-7 “R6” cell line nuclear protein. 
  
 
Figure 5. 14: Immunoblotting of Foxo3a in R2, R4, R6 and in normal MCF-7, 
MDA-MB-231 cell lines. 
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5.3.4 NF-κB 
 
5.3.4.1 Immunoblotting and Microarray results 
The CHUK gene encodes a member of the serine/threonine protein kinase 
family and this helps NF-κB be released into nucleus by help of MAP3K14. The levels 
of these two genes CHUK and MAP3K14 were 1.21 and 1.83 fold more in MCF-7 “R6” 
cells compared to normal MCF-7 cells. In parallel, NF-κB transcript variant 2 and 
variant 3 levels were 1.82 and 1.71 fold more in resistant cells. This implies that there is 
overactivation of non-canonical NF kappa B and it can be related to the CHUK gene.  
All levels of the NF-κB inhibitors were down except NFKBID. Its expression 
level was 0.63 fold lower than normal MCF-7 cells. IκB kinase complex and IκB kinase 
epsilon levels were nearly 2 times more in MCF-7 “R6” cells. 
NF kappa B pathway is transactivated nearly 2 times more in MCF-7 “R6” cells 
according to the gene expression level. This is confirmed by western blots in Figure 
5.16. 
Immunoblotting results also support the NF-kappa-B overactivation theory 
established according to the microarray results. In the western blot, a decreased level of 
IκB and an increased level of phoshorylated-IκB were seen as well as a high 
phosphorylated-IKK alpha/beta level at the basal state of the resistant cell. This shows 
that canonical NF-κB pathway become constitutively active in MCF-7 “R6” cells.  
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Table 5. 8: fold values of NF-κB entities. 
 
 
Figure 5. 15: Graph of folds showing NF-κB related gene expression. 
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Figure 5. 16: Western blot of NF-κB entities in MCF-7/R6 cells. A: IκB-alpha, B: 
Phospho-NF-κB, C: Phospho-IKK alpha/Beta, D: Phospho-IκB-alpha, E: Beta Actin 
 
IKK-Ɛ is part of the IKK complex. The level of IKK-Ɛ increased in MCF-7 “R6” 
cells. The basal IKK-Ɛ level in MDA-MB-231 cells is very low compared to MCF-7 
cells although β-actin level of MDA-MB-231 cells was slightly higher than MCF-7 
cells. The gene expression level of IKK-Ɛ was not in the significant list that because it 
had a p value higher than 0.05. Therefore, the gene expression and protein level were 
not compared. 
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Figure 5. 17: Immunoblotting of A: IKK-Ɛ and B: beta actin. C: Normal MCF-7, R: 
MCF-7 “R6” and MDA C: MDA-MB-231 cells. 
 
5.3.4.2 EMSA results for NF-kappa-B 
EMSA is performed through protein isolation of both normal MCF-7 and MCF-
7 “R6” cell lines. Cisplatin treatment was done to both cell lines for 15 minutes and 30 
minutes, also 1hour and 2 hour. A control not treated with cisplatin is used. 
Radioactively labeled NF-kB probe is used.  
At the basal state, there was no NF-κB activation in normal MCF-7 cells 
whereas there was strong activation of NF-κB in MCF-7 “R6” cells when C lanes were 
compared. When normal cells are treated with cisplatin (30µM), there is NF-κB 
activation in the 15 minute treatment, in 30 minute this effect is lost and in 1 hour NF-
κB reactivates again. In the 2 hour treatment, NF-κB degraded again. 
In MCF-7 “R6” cells, the basal state activation of NF-κB is seen. The cisplatin 
treatment does not change NF-kB activation drastically because it is already active at 
high ratio. In the 30 minute treatment, the NF-κB level reaches to maximum in the 
nucleus and then, its level is declined in the 1 hour and 2 hour treatment. However the 
level of NF-κB never decreases to basal state level. 
This study searched for the subunits of the NF-κB that have a role in 
transactivation. In order to understand this Super-shift assay needs to be done. In 
addition to NF-κB also p50 or p65 bands were expected to be seen. In figure 5.19, the 
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same level of NF-κB is seen which is indicated by the bottom arrow. The p50 (second 
lane) or p65 (third lane) are pointed with the arrow above. In the second lane there is a 
band that shows super shift. A very faint band in the third lane is seen however when 
these 2 were compared, band in lane 2 was more intense than in lane 3. So the subunits 
of activated NF-kB contain p50 subunit more than p65 subunit but transcription factor 
complex contains p65 as well. 
 
 
 
Figure 5. 18: Time dependent activation of nuclear NF-kB in both Normal MCF-7 
and MCF-7 R6” 
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Figure 5. 19: Super-shift assay for p50 and p65 in nuclear proteins of MCF-7 “R6”. 
The first lane contains free probe, second lane contains nuclear isolate of resistant cell 
and p50 antibody, the third lane contains nuclear isolate of resistant cell and p65 
antibody. 
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5.3.5 MAP Kinases 
 
 
 
Figure 5. 20: Microarray data of MAP Kinases A: Fold values B: Graph of fold 
values. 
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Figure 5. 21: Immunoblotting results of MAP kinases A: P-SAPK/JNK B: P-p38, 
C: P-ERK1/2 and D: Beta actin as a loading control. 
 
There are 3 known types of MAP kinases: ERK, JNK and p38. When MAP kinase is 
phosphorylated from superior kinase in the cell, it becomes activated. The most superior 
kinase of MAPK is MAP4K. The gene expression level of MAP4K2 decreased at 0.75 
fold in MCF-7 “R6” cells. MAP4K phosphorylates MAP3K. The gene expression level 
of MAP3K9 and MAP3K14 increased 1.56 and 1.83 fold respectively. MAP3K 
phosphorylates MAP2K. All MAP2K gene levels decreased except MAP2K2. 
MAP2K5, MAP2K6, MAP2K8 gene levels were 0.78-0.46 fold lower in MCF-7 “R6” 
cells.  MAP2K phosphorylates the lowermost kinase, MAPK. MAPK gene expression 
levels were increased with the exception of JNK1. JNK1 in other words MAPK8 levels 
were 0.18 fold lower in resistant cells. In sum, ERK3 and ERK6 (MAPK4, MAPK12), 
JNK2 (MAPK9) and p38B (MAPK11) levels were nearly 3 times more in MCF-7 “R6” 
cells. 
To sum up, MAP4K and MAP2K levels were lower whereas MAP3K and MAPK 
levels were higher in MCF-7 “R6” cells [Figure 5.20]. 
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At protein levels only the phosphorylation state of JNK, ERK and p38 was 
examined. Phospho-JNK at Thr183/Tyr185and Phospho-ERK at Thr202/Tyr204 levels 
declined in resistant cells. On the other hand, phospho-p38 levels increased in resistant 
cells. So ERK and JNK activation became lower whereas p38 became more active in 
MCF-7 “R6” cells. 
 
5.3.6 Some common proteins: p21 and p53 
The TP53 gene level becomes lower as the cells become drug resistant. In Figure 
5.22, fold graph shows that 0.21 fold lowness in p53gene in MCF-7 “R6” cells. Similar 
to the gene expression level, the intrinsic TP53 protein level is also low in 
chemotherapeutic resistant breast cancer cells. The p53 protein level becomes very 
similar to MDA-MB-231 which is intrinsically a cisplatin resistant cell. 
 
 
Figure 5. 22: p53 and p21 gene expression folds as A: table B: graph. 
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Figure 5. 23: Immunoblotting results of A: p21, B: p53, C: β-actin as a loading 
control. 
 
P21 is a cyclin-dependent kinase inhibitor. It regulates the cell cycle at the S phase. 
The expression of p21 is sometimes controlled by p53, sometimes the regulation of p21 
is independent from p53. The p21 level is increased in both gene expression and protein 
level. A 1.55 fold increment in the gene expression level is seen in the p21 gene. Figure 
5.23suggests that p21 is regulated independently from p53 because once p21 is 
increased, p53 gene level and protein level decreased. 
 
5.3.7 NFAT 
NFAT signaling studies are primarily done in immune cells. NFAT is a kind of 
sensor that reports the Ca
++
 level rise within the cell. NFAT1 is ubiquinated by MDM2 
which is a downstream target of GSK3B and Akt. There are many post-transcriptional 
modifications seen in NFAT.  
In this part of the project, total level of NFAT transcription factor was studied. 
NFATc3 gene expression was double that of MCF-7 “R6” cells. If increased level of 
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gene expression level continues, it is translated into protein therefore protein level of 
NFATc3 was checked by immunoblotting. The basal level of NFATc3 is nearly equal 
and slightly more in MCF-7 “R6” cells when compared to MDA-MB-231 cells. The 
NFATc3 protein level is less in normal MCF-7 cells when compared to resistant MCF-7 
cells and MDA-MB-231cells. The gene expression level is parallel with the protein 
level in the NFATc3 assessment. 
 
 
Figure 5. 24: A: Data table of NFAT gene expression level, B: Graph of NFAT 
gene expression levels, C: NFATc3 protein level. 
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5.3.8 Estrogen Receptor 
The estrogen receptor is a growth receptor which needs estrogen as a ligand. The 
estrogen Receptor (ER) and NF-κB expression levels are in contrast to each other 
reported in the literature [55]. Breast cancer cells growth is firstly dependent on the 
estrogen receptor level. At this phase growth of breast cancer cell can be inhibited by 
anti-estrogens such as tamoxifen. However after some time, cells become insensitive to 
this agent and estrogen, therefore, they develop into estrogen resistant cells. Our data 
shows that breast cancer anti-estrogen resistance 3 gene (BCAR3) levels is heightened 
at 2.1 fold in MCF-7 “R6” cells. This rise means that cisplatin resistant cell start to 
grow without needing estrogen and its receptor. And they become ER resistant cells 
[Figure 5.25]. 
  In previous results, the hyper-activation of NF-κB is seen [Figure 5.19]. Our data is 
consistent with the literature. ER levels are lower at 0.28-0.79 fold in MCF-7 “R6” 
cells. RelA expression is increased at 1.61 fold in resistant cells. Similar to MDA-MB-
231 cells and MCF-7 “R6” cells by means of RelA and ER, expression is seen. MDA-
MB-231 cells are ER-/- and the level of ER gene expression in MCF-7 “R6” became 
very similar to MDA-MB-231 cells. In previous studies, The RelA gene level is higher 
in MDA-MB-231 than MCF-7 cells is reported. And in this part of the project, level of 
RelA was higher in MCF-7 “R6” than in normal MCF-7 cells is seen. 
The Prolactin receptor level increased in MCF-7 “R6” cells. The overexpression of 
prolactin results in p53 gene downregulation which is seen in our data previously. 
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Figure 5. 25: Gene expression level of estrogen receptors. A: table of ER gene 
values, B: Graph of fold obtained from table. 
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5.4 Establishment of cisplatin-resistant MDA-MB-231 cell line 
 
MDA-MB-231 cells are intrinsically a cisplatin resistant cell line when compared to 
MCF-7 cells. Flow cytometry data of normal MDA-MB-231 shows that; without 
cisplatin treatment, control cells undergo apoptosis at 5-10%, and after 48 hours 
treatment of cisplatin, normal treated cells undergo apoptosis at 20-25%.  
The same “unique method1 for establishing MCF-7/R6 cell line is applied to MDA-
MB-231 cells. They are also treated with 1µM cisplatin for 4 days and 30µM cisplatin 
for 4 hours.  In the MDA-MB-231 “R2” cell line; there is a dramatic fall in apoptosis 
percent as seen in Figure 5.26. A 16% decrease in cell death is obtained. The detailed 
graph of MDA-MB-231 cell lines that are periodically treated with cisplatin is seen in 
Figure 26. Total protein is isolated from each cell line. This treatment is continued up to 
10 treatments over 1 year.  
Fluctuations in the apoptosis percent of MDA-MB-231/ R-5-R11 were seen, graphs 
of other 7 cell lines are not put here because they were not consistent. However, after 
“R2” cell line, cells became sensitized to cisplatin. The cell death ratios climbed 50%. 
Hence, intrinsic cisplatin resistant cells became sensitive to cisplatin with this method. 
Pretreatment with cisplatin affect cell viability and cells become resistant to drug at first 
but after the same procedure was applied periodically, cells become sensitive [Figure 
5.26, R3 and R4 columns].  
 
5.4.1 Cell morphology 
Cells become smaller as they are treated with more cisplatin. MDA-MB-231/R2 
cells became to be lifted up with trypsin easily, actually MDA-MB-231 cells are always 
lifted up more easily when it is compared to MCF-7 cells. But after “R2” cell line, this 
process became easier. 
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Figure 5. 26: Flow cytometry data as A:  table B: graph of 4 cisplatin treated MDA-
MB-231 cell line. 
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Figure 5. 27: Detailed flow cytometry graph of MDA-MB-231 “R2” cell line. Each 
flow cytometry experiment is done in triplicate. 
 
 
 
 
 
* 
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5.4.2 MAP kinases 
P38 and JNK are both stress and drug induced MAP kinases. P38 became to be 
constutively active when N and R2 lanes are compared at 0hour [Figure 5.28A: lane 1 
and 2]. In the MCF-7 cells, p-p38 levels were constutively active [Figure 28A and lane 
9]. Starting from the 0 hour, the early activation of p38 can be seen at the 1h, 3h and 6h 
treatments in MDA-MB-231 “R2” cells. P38 is activated after 0h and this is 
incrementally continued 6hours of treatment incrementally in both normal MDA-MB-
231 and MDA-MB-231 “R2”. However activation signals for MDA-MB-231 “R2” cells 
are always stronger when lanes next to each other were compared. The p-p38 arrow 
indicates 43kDa. 
 
 
 
Figure 5. 28: Immunoblotting results of MAP kinases A: p-p38, B: P-SAPK, C: P-
ERK and D: β-actin as a loading control. 
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Phospho-JNK level for both normal and MDA-MB-231/R2 cells were nearly same 
at the 0 hour but it is slightly more in MDA-MB-231/R2 cells. After 1 hour of treatment 
the 46 kDa (Figure 5.28B, upper arrow) band become intense and after 3hour treatment, 
54 kDa (Figure 28B, below arrow) band become intense and after 6 hour treatment both 
band intensity became stronger and JNK became activated at a high level in MDA-MB-
231 cells “R2”. On the other hand, in normal MDA-MB-231 cells, after 1 and 3 hours 
cisplatin treatment, no dramatic change occurred but after 6 hours of treatment, 54 kDa 
band become intense. In MDA-MB-231/R2 cells the 46 kDa band began to appear first 
whereas in normal MDA-MB-231 cells, the 54 kDa band started to appear first. 
 
Phospho-ERK1/2 protein level for both normal MDA-MB-231 cells and MDA-MB-
231 cells/R2 cells was same at the 0h cisplatin treatment. After 1hour to 6 hours of 
treatment of normal MDA-MB-231 cells, the ERK level increased slightly on the other 
hand, the ERK1/2 level increased more strongly from 1hour to 6 hour treatment in 
MDA-MB-231/R2 cells. In both cell lines the 44 kDa band became stronger. The top 
arrow indicates 42 kDa and the lower arrow indicates 44 kDa. β-actin was used as a 
loading control [Figure 5.28D]. 
 
 
5.4.3 NF –kappa-B 
The upper arrow indicates Phospho- IKK-α, 85 kDa and the bottom arrow indicates 
Phospho –IKK-β, 87 kDa [Figure 5.29A]. Phospho-IKK-α level of normal MDA-MB-
231 cells neither increased nor decreased in normal MDA-MB-231 cells in treated 
timepoints. However the Phospho-IKK-α level increased in MDA-MB-231 “R2” cells. 
The phospho –IKK-β level increased after 1 to 6 hours of cisplatin treatment in normal 
MDA-MB-231 cells. In contrast, Phospho–IKK-β level decreased in MDA-MB-231 
“R2” cells. At the 0 hour, Phospho-IKKα/β levels were lower in MDA-MB-231 “R2” 
cells. 
 
The arrow indicates the 40 kDa protein [Figure 5.29], Phospho-IκB-α. Phospho-
IκB-α is phosphorylated by-IKKα/β. The phospho-IκB-α level decreased in both normal 
MDA-MB-231 and MDA-MB-231/R2 cells. However, starting signal was more intense 
in normal MDA-MB-231 cells than MDA-MB-231/R2 cells [Figure 5.29B lane 1 and 
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5]. Once IκB-α is phosphorylated, it is targeted for degradation and NF-kappa-B is 
released therefore increased level of phosphorylated IκB-α means more NF-kappa-B 
release. Therefore in MDA-MB-231/R2 cells decreased level of NF-kappa-B signaling 
can be seen. MDA-MB-231 cells have constutive NF-kappa-B activation and as the 
cells become cisplatin resistant this activation level is lowered. 
 
 
 
Figure 5. 29: NF kappa B entities. A: Phospho-IKKα/β (Ser176/180), B: Phospho-
IκBα (Ser32), C: β-Actin. 
 
 
5.4.4 Foxo3a and Bcl-2 
Active forkhead members act as tumor suppressors and are involved in 
tumorigenesis. Increased expression of the Foxo family causes cell death. In this study, 
Foxo3a expression decreased in MDA-MB-231 “R2” cells slightly [Figure 5.30A]. But 
after 1 to 6 hours of cisplatin treatment the level of Foxo3a in both cell lines did not 
change. The upper arrow indicates 97 kDa; arrow below corresponds to 82 kDa. Both 
band intensities did not change over time. 
Bcl-2 is an anti-apoptotic protein that protects cell against cell death stimuli. The 
level of Bcl-2 is constant over time in both normal MDA-MB-231 and MDA-MB-231 
“R2” cells [Figure 5.30B]. However starting level of Bcl-2 was higher in MDA-MB-
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231 “R2” cells. These increments can reason that; cells are protecting itself from 
cisplatin caused cell death. Arrow in Figure 5.29B indicates 26 kDa. 
 
 
Figure 5. 30: Immunoblotting of different proteins. A: Foxo3a, B: Bcl-2 and C: β-
actin as a loading control. 
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6. DISCUSSION AND CONCLUSION 
 
 
 
 
Cisplatin is a chemotherapy agent used in the treatment of a variety of neoplasms 
and versatile cancers. Cisplatin has propensity to generate DNA damage, suppress DNA 
synthesis and RNA transcription, affect the cell cycle progression, and provoke 
apoptosis in cancer cells by impeding with the resistance mechanism [155]. It becomes 
activated inside the cell by substituting two cis-chloro “leaving” groups with water and 
subsequently engages to DNA with a covalent bond, results DNA adducts [125]. The 
oxidative and apoptotic effects of cisplatin are attributed to several properties of this 
prominent reactive intermediate. In some cases, after cisplatin-DNA complex 
formation, cells are arrested at G2 phase [124]. Pathway linking Pt-DNA adducts to 
apoptosis stays unrevealed. 
 
In recent years, cisplatin resistance (CR) is found to be existed as a natural 
mechanism against drug in cells. CR can be either intrinsic resistance or can be acquired 
resistance. Acquired resistance can be gained during cycles of application of the drug 
along the therapy by some effected organs with cancer such as ovarian, lung, colorectal. 
CR has a significant contribution to the pathophysiology of cancer progression, 
especially ovarian, testicular and breast cancer development. Despite the fact that, 
cisplatin is the most frequently studied drug, little is known about the drug and resistant 
mechanism. It is an astonishing fact that: there is no comprehensive study done on 
generating acquired cisplatin resistant breast cancer cell lines: MCF-7 and MDA-MB-
231 cells also detailed pathway analysis. Within this study, a newly established cisplatin 
resistant cell lines so called MCF-7/R6 and MDA-MB-231/R2 cells were investigated 
by means of genetic and proteomic level. Throughout the cell death analysis 
experiments, Annexin-V coupled with FITC dye was applied to the cells subsequently 
flow-cytometry method was used and resistant cell line was chosen accordingly.  MCF-
7 cells which have an apoptosis rate between 30-35% [10] started to undergo apoptosis 
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between 10-15% after being cisplatin resistant. And MDA-MB-231 cells which have an 
apoptosis rate between 20-25%, has started to have a new apoptosis rate, 7-10%. 
 
Of the numerous methods applied for generating drug resistance cell lines, our 
unique method is particularly promising because of application of the 2 graded drug 
doses. In this method cells are treated with the 2 different drug doses; first dose is the 
subtoxic low concentration dose (1 µM) which is given to the cells for long period (4 
day) and second dose is the toxic high concentration dose (30 µM) which is given to the 
cells for short period (4 hours). In the conventional methods: Treatments are done with 
the only one dose for constant period of time or concentration of the treatment starts 
with the low dose and then increases to the dose that is exceeding  the clinically relevant 
dose. The method we used comes through to the result rapidly by means of resistance at 
relatively high rate. 
 
 Recovery time required for MCF-7/R cells did not give relevant information about 
resistance status. On the other hand, MCF-7 /R6 cell morphology which was shifting 
towards to morphology of intrinsic resistant MDA-MB-231 cells was elucidative. 
Hardness of trypsinization was also pointing cytoskeletal and attachment changes albeit. 
MCF-7/R6 cells were also cryo-resistant since after thawing of cells and treating cells 
with cisplatin, apoptosis rate did not differed compared to initial response. 
 
There are several reports indicating that; some drug-specific resistant cell lines show 
cross-resistance to other drugs in addition to drug we are currently treating with. We 
wanted to question if this hypothesis was true for MCF/R cell line. To test this, we 
examined 2 different classes of anti-cancer agents which were Docetaxel and Paclitaxel 
on MCF-7/R6 for the same treatment period of cisplatin. Our results clearly indicated 
that; Cisplatin resistant MCF-7 cells were also resistant to Docetaxel and Paclitaxel at 
5% and 16% increase at death rate respectively. Further investigations done in 
microarray showed that; Responsible multi-drug resistance genes (MDR/TAP) were 
identified in this study and they were: SLC31A1, ABCB6 and ABCB9. Gene 
transcription level increased at 2 fold in the resistant cell line at basal state. 
Consequently, transcription of these 3 gene level can be used as a drug resistance 
marker in clinics for MCF-7 cells. 
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Previous studies reported that; many resistant cell lines show altered drug uptake 
and processing in pathways. Glutathionine S-transferases (GSTs) are important 
enzymes that catalyze conjugation of glutothionine to drug in order to make compound 
more anionic and eventually to pump the drug out of the cell more easily by ATP 
dependent glutothionine S-conjugate export (GS-X) pump namely, MRP1 and MRP2 
[126]. Our results demonstrated that; glutathione S-transferase pi (GSTP1) is the 
version of overly transcribed gene encoding drug exporter channel. In addition to that 
transcription of microsomal glutathione S-transferase 1 (MGST1), metallothionein 1F 
(MT1F) and metallothionein 1H (MT1H) increased nearly 2 fold in MCF-7/R6 cells. 
Consequently cisplatin is exported to outside of the breast cancer cell by elevating 
expression level of these genes. Microsomal glutathione S-transferase 1(MGST1) is a 
novel gene found in MCF-7 /R6 cells and transcribed 2 times more in this cell. 
Although much has been published on the drug resistant marker genes activated in drug 
resistant cells, the discovery of which version of drug resistant genes were 
transactivated in drug resistant breast cancer cells were firstly identified in this thesis. 
Further evidence for cisplatin resistant cells were also resistant to the other drug 
anti-cancer agents were provided from the results obtained by pre-incubating the non-
resistant MCF-7 cells with serum of resistant cells prior to the anti-cancer agent 
treatment. Serum of resistant cells was obtained after 4 days of passaging MCF-7/R6 
cells. Serum was divided into 2 groups; one group was filtered with 0.22µm filter, and 
the another group was not filtered. Filtered serum was able to inhibit apoptosis by 20% 
decline at death rate of normal MCF-7 cells. Non-filtered serum caused more cell death 
except for Docetaxel treatment. Due to the activation of cell survival pathways, filtered 
serum increased cell survival. So the factor causing this effect can be a ligand found in 
the serum which activates cell survival signaling mechanisms such as NF-kappa-B. 
Later in this study, NF-kappa-B is understood to be constutively active by selecting p50 
subunit dimerization. 
In the following part of the study, microarray was conducted to have aspect of 
global gene transcription data. Illumina Human WG-6 BeadChip array was used for 
gene expression analysis. MATLAB 2009b was used for statistical analysis. 
Explanation of the written code was done in detail in the result section. This code found 
10 marker genes among 48,803 genes. Genes are PINK1, TPCN2, P2RY2, CCNG1, 
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GSK3B, FLAD1, KEAP1, ACTA2, RWDD2A and YRDC. Latter 2 genes are not 
characterized well until now. But former 8 genes are related to; mitochondria 
metabolism, Ca
++
 metabolism, G protein coupled receptor, cell cycle, WNT pathway, 
FAD co-enzyme, cytoprotective, cytoskeleton respectively. These 10 genes intersect at 
some points. ACTA2 and GSK3B genes intersect at non-canonical WNT pathway. 
CCGN1 gene and WNT pathway intersect at p21 and p53 gene. TPCN2 and P2RY2 
both encodes for channel and receptor that may be responsible for efflux of drug to 
outside of the cell. Both PINK1 and KEAP genes are overexpressed in drug resistance 
cells. FLAD1 gene is related to DNA and it intersects with p53 gene. So all 10 genes are 
related to each other and they may establish a new pathway that is directly related to 
cisplatin resistance in MCF-7 cells. 
A very well documented transcription factor, NF-κB, has emerged as a key mediator 
of a wide variety of cellular processes which is involving; growth, differentiation, and 
survival [131].  Overexpression of IκB-α or IκB-β which are upstream molecule of NF-
κB reduces the constitutive activity of the NF-κB/CAT reporter gene in the MDA-MB-
231 cell line. Thus, reduced expression of either IκB-α or IκB-β is sufficient for 
constitutive activation of NF-κB [55]. In this part of the study, we tried to differentiate 
if NF-κB binding to DNA is constitutive or inducible and also we tried to find out 
canonical or non- canonical NF-κB pathway is activated. Transactivation properties of 
NF-κB in acquired drug resistant and in normal adenocarcinoma breast cancer cell lines 
(MCF-7) were also checked by treating cells with cisplatin. A direct positive correlation 
of constitutive NF-κB-DNA binding in MCF-7/R6 and early transactivation of NF-κB 
in acquisition of drug resistance properties of a breast cancer cell line is seen in EMSA. 
Canonical NF-κB pathway activation was documented in MCF-7/R6 cells by 
Immunoblotting experiment.  
Before activation of NF-κB subunits, they can undergo either homo- or hetero-
dimerization in the cytoplasm in this way it that binds to promoter regions which is 
decameric sequences of both cellular and viral genes [45-48, 72]. In detailed analysis, 
we have shown precisely that activated NF-κB contains mostly subunits of p50 
subsequent to p65 which in turn induces p50-p50 or p50-p65 dimmer formation and 
subsequently activates transcription of cell survival target genes and in turn cell survival 
mechanism albeit. Recently, Zhou et al. suggested that the p50 transactivation in the 
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nucleus of ER positive breast cancer cells might be used as a prognostic marker in a 
subset of patients [132,133]. As part of the non-canonical NF-κB pathway activation, 
the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NF-κB2/p100 
associated with Rel B. It induces proteolytic processing and NF-κB-RelB-p52 complex 
formation. In our study, gene expression of both CHUK and MAP3K14 also NFKB2 
levels increased in resistant cell.  
 
Gene transcription level sometimes does not directly correlates to protein level. For 
instance, gene expression level of IκB-α and IκB-β is increased in MCF-7/R6 cells 
however at protein level both IκB started to be degraded. Eventually level of them 
decreased whereas Phospho- IκB level is increased because phosphorylation of IκB 
ends with degradation. In immunoblotting,  low level of IκB and high level of P- IκB 
was seen in addition to that high P-IKK α /β level at basal state of resistance cell tells us 
canonical NF-κB pathway become constutively active in MCF-7/R6 cells. The same 
inverse correlation was seen in MAPK gene and protein expression level. JNK and 
ERK1/2 activation is decreased in MCF-7/R6 cells at protein level whereas JNK and 
ERK1/2 gene expression level increased in the same cell line. 
 
Increasing of prolactin receptor level and declining of estrogen receptor level 
downregulates p53 gene [135]. And p53 gene works inversely with the p21 gene. 
Prolactin receptor also activates both Jak–Stat and MAPK pathway [136] which was the 
case also in this study. Increased expression of prolactin and decreased expression of 
ER is seen here and this results P53 gene downregulation and p21 gene is 
transactivation. In intrinsic cisplatin resistant cell which isMDA-MB-231, p53 is mutant 
and found to be very low level. 
ER represses NF-κB pathway in normal MCF-7 cells and also Estrogen receptor 
(ESR1 gene) loss cause AP-1 activation but this finding remains controversial [55, 127-
130]. As claimed by many authors, our data showed that ER (ESR1 and GPER), ER 
binding site (EBAG9) and Estrogen receptor regulated inhibitor (RERG) RNA level is 
declined to half compared to control. Supported by literature, this caused NF-κB 
activation being constutive. ER receptor is absent in MDA-MB-231 cells and there is an 
analogy seen in MCF-7/R6 cisplatin resistant cell. ER receptor expression declination 
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can confer that; one of the important resistance mechanism element candidates should 
be that. 
 
Foxo-1 is phosphorylated by AKT1 which is an insulin stimulated protein. IGF1 
rapidly induces phosphorylation of Ser-256, Thr-24, and Ser-319. When Foxo-1 is 
phosphorylated from Ser-256 residue, affinity to DNA decreases and this promotes the 
phosphorylation of Thr-24, and Ser-319, permitting phosphorylation of Ser-322 and 
Ser-325, probably by CK1, and this leads to nuclear exclusion and loss of function. 
Foxo-1 is phosphorylated upon DNA damage, probably by ATM or ATR [111-115]. 
When Foxo-1 is silenced with siRNA technology, apoptosis of fibroblast is reversed at 
76% [116]. In our study, Foxo-1 level is decreased both at gene and protein level. 
Phosphorylation of Foxo-1 at Ser 256 and Thr-24 is seen obviously in cisplatin 
resistance phenotype. As Foxo-1 phosphorylated, total Foxo-1 level is decreased.  
 
Pro-apoptotic members whose levels are down in MCF-7/R6 cells are; Apaf-1, BID, 
Caspase-6, CFLAR, CRADD, TUSC1, TUSC4, XAF1 and FOXO-1, FOXO-4. The 
level of BCL, DAP, DAPK and ATG are increased in MCF-7/R6. We also confirmed 
Apaf-1 declination and Aven and XIAP increment by Immunoblotting. 
 
NFAT is a transcription factor that is activated after Ca
+2
 rise in the cell. Level of 
NFATc3 was checked by immunoblotting and increment was seen. TPCN2 and 
NFATc3 gene levels increased in MCF-7/R6 cells. 
 
Generally, SAPK/JNK and p38 are key mediators of stress and inflammation 
responses evoked by a variety of physical, chemical and biological stress stimuli on the 
other hand ERK 1/2 cascade is mostly induced by growth factors [134]. In normal 
MDA-MB-231 cells, there is no constitutive activation of MAP kinases. Activation of 
MAP kinases in response to cisplatin is already known. But in MDA-MB-231 “R2” cell 
line, there is constitutive activation of all MAP kinases and also early activation of all 3 
kinases; p38, ERK1/2 and JNK when cisplatin is given 0 hour to 6 hours. On the other 
hand, MAP kinases in MCF-7 behave individually. JNK and ERK1/2 activation was 
lowered but p38 activation was heightened in MCF-7/R6 cell line. 
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Also Foxo3a which is a tumor suppressor protein was downregulated and Bcl-2 
which is anti-apoptotic protein was upregulated in MDA-MB-231 “R2” cell line. 
 
Phospho-IKKα/β and in parallel to this Phospho-IκB-α level is downregulated after 
0 hour to 6 hours cisplatin treatment in MDA-MB-231 “R2”cells.  
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7. FUTURE STUDIES 
 
 
 
 
Since filtered serum of MCF-7/R6 cells gained normal cell a resistance status, 
filtered serum studies should be progressed and serum should be used on normal MCF-7 
cells but this time, protein isolation and cross resistance should be checked. 
Protein-protein interaction of 10 genes which resulted from microarray analysis 
should be study more; there may be new pathway links which will establish and they 
may be drug resistance marker genes for MCF-7 type breast cancer. One output can be; 
NFATc2 and TPCN2 may be correlated. Because they are both activated through Ca
+2
 
metabolism. 
Foxo-1, Foxo-3, Foxo-4 needs to be examined at protein level and for protein-
protein interaction because their level changed significantly between normal and 
resistant MCF-7 cells. 
NF-κB activation in MDA-MB-231/R2 needs to be examined in more detail. 
Because some increments and decline of some subunits was inconsistent, when they 
differentially thought. Outcome of examined subunits may result downregulation of 
canonical NF-κB pathway. 
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APPENDIX A 
 
 
CHEMICALS 
 
(in alpabetical order) 
Name of chemical Supplier Company Catalog number 
2-Mercaptoethanol Fluka, Switzerland 63700 
Acrylamide/Bis-Acrylamide Sigma, Germany A3699 
Agarose AppliChem, Germany   
Ammonium persulfate Sigma, Germany A3768-25G 
Bradford Solution Biorad Inc., USA 500-0006 
CM-H2DCF-DA Fluka, Switzerland WA12820 
EDTA Riedel-de Haén, Germany 27248 
Ethanol Riedel-de Haén, Germany 32221 
Glycine Molekula, UK M10795955 
HCl Merck, Germany 100314 
Hepes Molekula, UK M55704197 
Isopropanol Merck, Germany 1009952500 
KCl Fluka, Switzerland 60129 
KH2PO4 Riedel-de Haén, Germany 4243 
Liquid nitrogen Karbogaz, Turkey   
Methanol Sigma-Aldrich 24229 
Na2HPO4 Merck, Germany 1065791000 
NaCl Duchefa Biochemie S05205000 
NP-40 Sigma, Germany I3021 
Penicilin/Streptomycin PAN, Germany P06-07100 
Phosphatase Inhibitor coctail tablet Roche, Germany 4906837001 
PMSF Amresco®,USA 0754-25G 
Protease Inhibitor coctail tablet Roche, Germany 4693124001 
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Sodium Dodecyl Sulphate Sigma, Germany L4390 
TEMED Sigma, Germany T7024-100ml 
Tris Molekula, UK M11946779 
Trypsin/EDTA PAN, Germany P10-0231SP 
Tween 20 Molekula, UK 18945167 
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APPENDIX B 
 
 
 
ANTIBODY 
 
(in alpabetical order) 
 
Nameo of Antibody Supplier Company Catalog 
number 
Annexin V-FITC Alexis Biochemicals ALX-209-250-
T100 
Anti p50 ab     
Anti p65 ab     
Anti-Apaf-1 ab Cell Signal Tech., USA 5088 
Anti-Aven     
Anti-Bcl-2 Cell Signal Tech., USA   
Anti-Foxo1 ab Cell Signal Tech., USA   
Anti-Foxo3a ab Cell Signal Tech., USA   
Anti-Foxo4 ab Cell Signal Tech., USA   
Anti-IKK-ε ab Cell Signal Tech., USA   
Anti-IκB-α ab Cell Signal Tech., USA   
Anti-mouse IgG HRP ab Cell Signal Tech., USA 7076 
Anti-NFATc3 ab     
Anti-p21 ab Cell Signal Tech., USA 2946 
Anti-p53 ab Cell Signal Tech., USA 9282 
Anti-p-ERK 1/2 ab Cell Signal Tech., USA 4376 
Anti-p-Foxo1 ab Cell Signal Tech., USA   
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Anti-p-Foxo1 ab #2 Cell Signal Tech., USA   
Anti-p-IKK-α/β ab Cell Signal Tech., USA   
Anti-p-IκB-α ab Cell Signal Tech., USA   
Anti-p-JNK ab Cell Signal Tech., USA 9251 
Anti-p-NFκB/p65 ab Cell Signal Tech., USA   
Anti-p-p38 ab Cell Signal Tech., USA 4631 
Anti-rabbit IgG HRP ab Cell Signal Tech., USA 7074 
Anti-XIAP ab Santa Cruz Biotechnology Inc., USA   
Anti-β-actin ab Cell Signal Tech., USA 4967 
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APPENDIX C 
 
MOLECULAR BIOLOGY AND CELL CULTURE MATERIALS 
 
Name of material Supplier Company Catalog 
Number 
ECL Advance Chemiluminescence Amersham Biosciences, 
UK 
RPN2135 
Blocking agent ECL Advanced 
TM
 
blocking agent 
CPK1075 
Hyperfilm ECL Amersham Biosciences, 
UK 
RPN2103K 
Page Ruler Prestained Ladder Fermentas, Germany #SM1811 
PVDF membrane Roche, Germany 3010 
Dulbecco's Modified Eagle Medium Pan Biotech, Germany   
Fetal Bovine Serum PAN, Germany   
Cisplatin Sigma, Germany   
Developer Solution Agfa, USA   
Bradford dye     
Whatman Papers     
Trypsin 0,25 %/EDTA 0,02 % in PBS 
with Phenol red 
  P10-019100 
Trypsin 0,05 %/EDTA 0,02 % in PBS 
with Phenol red 
   P10-
023100SP 
2X RNA Loading Dye Fermentas, Germany #R0641 
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APPENDIX D 
 
 
EQUIPMENTS 
 
Name of material Supplier Company 
Autoclave: Hirayama, Hi-Clave HV-110, JAPAN 
Balance: Sartorius, BP211D, GERMANY 
Centrifuge: 
  
  
Eppendorf, 5415D, GERMANY 
Eppendorf, 5415R, GERMANY 
Kendro Lab. Prod. Heraues Multifuge 3L, GERMANY 
Deepfreeze: -70
0
C, Kendro Lab. Prod. Hearus Hfu486 Basic, 
GERMANY 
  -20
0
C, Bosch, TURKEY 
Distilled Water: Milipore, MiliQ Academic, FRANCE 
Electrophoresis: Biorad Inc., USA 
Flow Cytometry: BD Biosciences FACS Canto
TM
, USA 
Ice Machine: Scotsman Inc., AF20, USA 
Incubator:  
Laminar Flow: Kendro Lab. Prod. Heraues, HeraSafe, HS12, 
GERMANY 
Magnetic Stirrer: VELP Scientifica, ARE Heating Magnetic Stirrer, 
ITALY 
Microliter Pipette: Eppendorf, Research 
Microwave Oven: Bosch, TURKEY 
pH meter: WTW, pH540 GLP MultiCal®, GERMANY 
Power Supply: Biorad, PowerPac 300, USA 
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  Wealtec, Elite 300, USA 
Refrigerator: Bosch, TURKEY 
Shaker: Stuart® Gyratory rocker, SSL3, USA 
Thermocycler: Eppendorf, Mastercycler Gradient, GERMANY  
Water Bath: Huber, Polystat cc1, GERMANY 
Gel Dryer E-C Apparatus Corp. EC355, USA 
Hemacytometer   
Cell culture 
products 
TRP, SWITZERLAND 
Transfer apparatus Biorad, PowerPac 300, USA 
Gel 
documentatiton 
UVITEC, UVIdoc Gel Documentation System,UK 
BIO-RAD, UV-Transilluminator 2000, USA 
 
